WO2004007683A2 - Reprogrammation cellulaire dans un hydrogel peptidique et utilisations associees - Google Patents

Reprogrammation cellulaire dans un hydrogel peptidique et utilisations associees Download PDF

Info

Publication number
WO2004007683A2
WO2004007683A2 PCT/US2003/021981 US0321981W WO2004007683A2 WO 2004007683 A2 WO2004007683 A2 WO 2004007683A2 US 0321981 W US0321981 W US 0321981W WO 2004007683 A2 WO2004007683 A2 WO 2004007683A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
growth factor
differentiation
peptides
Prior art date
Application number
PCT/US2003/021981
Other languages
English (en)
Other versions
WO2004007683A3 (fr
Inventor
Carlos Semino
Collette Shen
James Sherley
Shuguang Zhang
Original Assignee
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute Of Technology filed Critical Massachusetts Institute Of Technology
Priority to AU2003274900A priority Critical patent/AU2003274900A1/en
Publication of WO2004007683A2 publication Critical patent/WO2004007683A2/fr
Publication of WO2004007683A3 publication Critical patent/WO2004007683A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0671—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins

Definitions

  • the present invention relates to techniques for inducing the differentiation and transdifferentiation of progenitor cells.
  • the invention includes compositions and methods involving encapsulation of various cells including progenitor cells or stem cells, h particular, the invention involves the use of nanoscale materials such as peptide hydrogels in such techniques.
  • l ⁇ f 100 divide and generate additional self-renewing stem cells, and also to give rise to cells that are able to differentiate along various differentiation pathways.
  • stem cell technology has led to the development of important research tools such as transgenic mice and also enabled medical treatments such as bone marrow transplants and gene therapy for certain diseases. From a research point of view, an enhanced understanding of stem cell biology is likely to have a significant impact on areas ranging from development to aging and cancer. Stem cell technology also promises to yield numerous additional medical applications. For example, stem cells could prove extremely useful in tissue engineering, a multidisciplinary field that seeks to develop in vitro cell and cell/material systems and structures that can be used to repair or replace damaged or diseased tissues or organs.
  • stem cells and other progenitor cell types that may lack self- renewal capacity and/or have a more restricted differentiation potential can be fully realized. Understanding of the factors that trigger and control stem cell division and differentiation remains incomplete. It is thought that such cells respond to a variety of cues, which may include growth factors, cell-cell contacts, and structural features of the extracellular environment among others. Many studies of stem cells involve the removal of cells from one animal followed by transplantation into another individual and subsequent examination of the ability of the transplanted cells to give rise to a diversity of cell types. While useful in terms demonstrating the existence and potential of stem cells, such approaches are limited.
  • liver progenitor cells and stem cells The regenerative capacity of the body is particularly striking in the case of certain organs such as the liver, which is well-known to possess extensive capacity to regenerate after insults ranging from partial hepatectomy to toxin-induced injury.
  • organs such as the liver
  • understanding of liver stem cells remains limited, and the potential of liver-derived cells has not been fully explored. Therefore, there is a need for the development of improved cell culture systems, techniques, and compositions for the propagation of liver progenitor cells and stem cells and for exploiting their differentiation and transdifferentiation potential, addition, there is a need for the development of improved cell culture systems, techniques, and compositions for the propagation of various other progenitor or stem
  • 35S3475vl cells including neural lineage cells, and for exploiting their differentiation and transdifferentiation potential.
  • the invention represents the convergence of research in the fields of progenitor and stem cells and biomaterials.
  • the inventors have discovered that self- assembling peptide hydrogel structures derived herein support the differentiation and transdifferentiation of cells.
  • the invention provides a macroscopic structure comprising amphiphilic peptides, wherein the peptides comprise substantially equal proportions of hydrophobic and hydrophilic amino acids, are complementary and structurally compatible, and are capable of self-assembling into a beta-sheet macroscopic structure, and a population of progenitor cells.
  • the progenitor cells are encapsulated in the structure.
  • the macroscopic structure further comprises a differentiation-enhancing or transdifferentiation enhancing agent, e.g., a growth factor or extracellular matrix (ECM) component.
  • a differentiation-enhancing or transdifferentiation enhancing agent e.g., a growth factor or extracellular matrix (ECM) component.
  • ECM extracellular matrix
  • the term "differentiation enhancing agent” shall be understood to include agents that enhance, stimulate, or contribute to differentiation and/or transdifferentiation.
  • the peptide structure renders the cells permissive for instruction by the agent.
  • the progenitor cells are derived from the liver.
  • the invention further provides methods of culturing cells comprising (i) providing progenitor cells or stem cells, and (ii) contacting the progenitor cells with a cell culture material comprising amphiphilic peptides, wherein the peptides comprise substantially equal proportions of hydrophilic and hydrophobic amino acids, are complementary and structurally compatible, and are capable of self- assembling into a beta-sheet macroscopic structure.
  • the progenitor cells or stem cells may be encapsulated within the peptide structure by (i) incubating the peptides and the progenitor cells in an aqueous solution comprising an iso-osmotic solute; and (ii) adding an electrolyte to the solution sufficient to initiate self-assembly of the peptides into a beta-sheet macroscopic structure, whereby the cells are encapsulated by the formation of the scaffold.
  • the method may further include adding a
  • differentiation-enhancing or transdifferentiation enhancing agent such as a growth factor or ECM component, either before self-assembly or to media in which the cell/peptide structure is incubated.
  • agent causes a portion of the progenitor cells or their progeny to transdifferentiate.
  • the macroscopic structure renders at least a portion of the progenitor cells permissive for instruction by the agent.
  • the progenitor cells are derived from the liver.
  • the invention provides methods of culturing cells comprising encapsulating the cells in a three-dimensional nanoscale environment scaffold.
  • the nanoscale environment scaffold comprises a protein or peptide hydrogel.
  • the hydrogel may be a self- assembling peptide hydrogel as described herein.
  • the peptides comprise amphiphilic peptides, wherein the peptides comprise substantially equal proportions of hydrophilic and hydrophobic amino acids, are complementary and structurally compatible, and are capable of self- assembling into a beta-sheet macroscopic structure.
  • the nanoscale environment scaffold comprises nanofibers.
  • the nanofibers may be comprised of self-assembling peptides, e.g., any of the peptides described herein.
  • the cells comprise or consist of progenitor cells.
  • the cells comprise or consist of stem cells.
  • the cells comprise liver-derived cells or cells derived from neural tissue.
  • the cells comprise progenitor cells or stem cells that have been instructed or induced to differentiate. For example, the cells may be instructed or induced to differentiate along a liver cell lineage pathway, along a neural lineage pathway, or along a pancreatic lineage pathway.
  • the cells may comprise liver cells (e.g., liver progenitor cells, liver stem cells, hepatocytes, oval cells, bile duct cells), neural lineage cells (e.g., neurons or glia), and/or pancreatic lineage cells (e.g., endocrine cells such as ⁇ , ⁇ , ⁇ , or ⁇ cells or exocrine cells).
  • liver cells e.g., liver progenitor cells, liver stem cells, hepatocytes, oval cells, bile duct cells
  • neural lineage cells e.g., neurons or glia
  • pancreatic lineage cells e.g., endocrine cells such as ⁇ , ⁇ , ⁇ , or ⁇ cells or exocrine cells.
  • the invention further provides nanoscale environment structures and scaffolds encapsulating cells. These terms are generally used interchangeably herein.
  • the scaffolds encapsulating cells may be prepared according to the methods described herein or variations thereof.
  • the nanoscale environment scaffold comprises a protein or peptide hydrogel.
  • the hydrogel may be a self-assembling peptide hydrogel as described herein.
  • the peptides comprise amphiphilic peptides, wherein the peptides comprise substantially equal proportions of hydrophilic and hydrophobic amino acids, are complementary and structurally compatible, and are capable of self-assembling into a beta-sheet macroscopic structure, h certain embodiments of the invention the nanoscale environment comprises or consists of an artificial material.
  • the artificial material comprises or consists of a material not naturally found in the body. Artificial material also encompasses certain materials obtained by isolating and processing substances produced by a living source. However, a material that remains substantially intact and substantially retains the structure in which it is naturally found within the body of an organism is not considered an artificial material. Any of a variety of artificial materials may be used.
  • the nanoscale environment scaffold comprises nanofibers. The nanofibers may be comprised of self-assembling peptides, e.g., any of the peptides described herein.
  • the cells comprise isolated cells, e.g., cells that are not in their natural environment within the body of a subject.
  • the cells may comprise cells that have been removed from a subject. Such cells may have been cultured following removal prior to encapsulation.
  • the cells may comprise a cell line.
  • the cells comprise or consist of progenitor cells.
  • the cells comprise or consist of stem cells.
  • the cells comprise liver-derived cells or cells derived from neural tissue.
  • the cells comprise stem cells or progenitor cells that have been instructed or induced to
  • the cells may be instructed or induced to differentiate along a liver cell lineage pathway, along a neural lineage pathway, or along a pancreatic lineage pathway.
  • the cells may comprise liver cells (e.g., liver stem cells, liver progenitor cells, hepatocytes, oval cell, bile duct cells), neural lineage cells (e.g., neurons or glia), and/or pancreatic lineage cells (e.g., endocrine cells such as ⁇ , ⁇ , ⁇ , or ⁇ cells or exocrine cells).
  • liver cells e.g., liver stem cells, liver progenitor cells, hepatocytes, oval cell, bile duct cells
  • neural lineage cells e.g., neurons or glia
  • pancreatic lineage cells e.g., endocrine cells such as ⁇ , ⁇ , ⁇ , or ⁇ cells or exocrine cells.
  • the nanoscale environment scaffold encapsulating cells may encapsulate a combination of different cell
  • the invention provides methods of treating an individual comprising (i) identifying an individual in need of treatment; and (ii) administering a nanoscale environment scaffold encapsulating cells to the individual.
  • the nanoscale environment scaffold encapsulating cells may comprise or consist of stem cells or progenitor cells.
  • the cells comprise liver cell lineage cells, neural lineage cells, or pancreatic lineage cells.
  • the cells comprise stem cells or progenitor cells that have been instructed or induced to differentiate. The cells may be instructed or induced to differentiate along a liver cell lineage pathway, along a neural lineage pathway, and/or along a pancreatic lineage pathway.
  • the cells may comprise liver cells (e.g., liver stem cells, liver progenitor cells, hepatocytes, oval cells, bile duct cells), neural lineage cells (e.g., neurons or glia), and/or pancreatic lineage cells (e.g., endocrine cells such as ⁇ , ⁇ , ⁇ , or ⁇ cells or exocrine cells).
  • liver cells e.g., liver stem cells, liver progenitor cells, hepatocytes, oval cells, bile duct cells
  • neural lineage cells e.g., neurons or glia
  • pancreatic lineage cells e.g., endocrine cells such as ⁇ , ⁇ , ⁇ , or ⁇ cells or exocrine cells.
  • the cells comprise cell types that are normally found within a three- dimensional environment within the body.
  • the cell types preferably are not naturally found in a cartilaginous
  • the cells preferably do not include chondrocytes or chondrocyte precursor cells.
  • the invention provides methods of treating an individual comprising (i) identifying an individual in need of treatment; and (ii) administering cells to the individual, wherein the cells have been induced to differentiate or transdifferentiate by culturing them encapsulated in a cell culture material comprising amphiphilic peptides, wherein the peptides comprise substantially equal proportions of hydrophilic and hydrophobic amino acids, are complementary and structurally compatible, and are capable of self-assembling into a beta-sheet macroscopic structure.
  • the cells are exposed to a differentiation or transdifferentiation enhancing agent.
  • the cells may be extracted from the structure prior to administration or the cell/peptide structure may be introduced into the individual.
  • the invention provides a cell culture kit comprising (i) amphiphilic peptides, wherein the peptides comprise substantially equal proportions of hydrophilic and hydrophobic amino acids, are complementary and structurally compatible, and are capable of self-assembling into a beta-sheet macroscopic structure; and (ii) instructions for initiating self-assembly of the peptides into a macroscopic structure.
  • the kit may further comprise at least one element selected from the group consisting of: a population of cells, cell culture medium, a predetermined amount of a growth factor, a predetermined amount of an electrolyte, instructions for encapsulating cells within a peptide hydrogel structure and for other uses of the system, instructions for inducing cells to differentiate or transdifferentiate within the scaffold, a vessel in which the encapsulation may be performed, a liquid in which the peptide can be dissolved, an electrolyte for initiating peptide self-assembly, medium for tissue culture, and one or more differentiation-enhancing agents.
  • the invention provides an assay system comprising a population of cells derived from the liver or their progeny, wherein the cells express a cytochrome P450 enzyme, and wherein the cells are encapsulated in a beta-sheet macroscopic scaffold comprising peptides that comprise substantially equal proportions of hydrophilic and hydrophobic amino acids, are complementary and
  • the assay system may further comprise a substrate for the cytochrome P450 enzyme.
  • the invention provides methods of testing a compound comprising steps of (i) contacting a population of cells derived from the liver or their progeny, wherein the cells express a cytochrome P450 enzyme, and wherein the cells are encapsulated in a beta-sheet macroscopic scaffold comprising peptides that comprise substantially equal proportions of hydrophilic and hydrophobic amino acids, are complementary and structurally compatible, and are capable of self- assembling into a beta-sheet macroscopic structure, with the compound; (ii) measuring activity of the cytochrome P450 enzyme; and (iii) comparing the level of activity of the enzyme in the presence of the compound with level of activity in the absence of the compound.
  • the invention further provides a method of testing a compound comprising steps of (i) contacting a population of cells derived from the liver or their progeny, wherein the cells express a cytochrome P450 enzyme, and wherein the cells are encapsulated in a beta-sheet macroscopic scaffold comprising peptides that comprise substantially equal proportions of hydrophilic and hydrophobic amino acids, are complementary and structurally compatible, and are capable of self-assembling into a beta-sheet macroscopic structure, with the compound, (ii) measuring activity of the cytochrome P450 enzyme; and (iii) comparing the level of activity of the enzyme in the presence of the compound with level of activity in the absence of the compound.
  • the present invention refers to various patents, patent applications, books, and publications in the scientific literature. The contents of all such items are incorporated herein by reference in their entirety.
  • the present invention may employ standard cell culture techniques and media and standard molecular biological and immunological protocols such as are found in reference works such as Freshney. R.
  • Figure 1 is a schematic illustration showing the hypothetical interactions between peptides in an assembled peptide structure.
  • Figure 2 is a picture of assembled peptide structures formed in a variety of predetermined shapes.
  • Figure 2a shows a tape-shaped scaffold structure.
  • Figure 2b shows a string-shaped scaffold structure.
  • Figure 2c shows a sheet-like scaffold structure.
  • Figure 3 shows encapsulation of adult LPCs in an assembled peptide structure.
  • Figure 3 a shows encapsulated LPCs immediately after encapsulation.
  • Figure 3b shows encapsulated LPCs two days after encapsulation.
  • Figure 3c shows spheroid formation by adult LPCs encapsulated in an assembled peptide structure four to five days after encapsulation.
  • Figure 3d shows the same spheroid as in Figure 3c, after staining for incorporation ofBrdU into DNA.
  • Figure 4 presents data on CYPIAI activity of LPCs growing under various culture conditions.
  • Figure 4a shows CYPIAI activity of LPCs growing as a monolayer on a standard plastic culture dish.
  • Figure 4b shows CYPIAI activity of LPCs spheroids growing in an assembled peptide structure two weeks after encapsulation.
  • Figure 4c is a graph showing CYPIAI activity of LPC spheroids growing in an assembled peptide structure during a time course of two weeks, starting 24 hours after encapsulation.
  • Figure 4d is a graph showing comparative CYPIAI activity of LPCs maintained under various culture conditions: monolayer on plastic dish with low (1%) serum concentration (serum starvation); spheroid culture obtained by growing LPCs in
  • 3583475V1 10 ⁇ f l 0 ° liquid culture at high density; spheroid culture in assembled peptide structure growing in DMEM with 10% FBS; spheroid culture in assembled peptide structure growing in HGM.
  • Figure 5 shows LPCs growing in an assembled peptide structure after staining for various neuronal markers.
  • Figure 5b shows LPCs stained for Nestin.
  • Figure 5d shows LPCs stained for ⁇ -tubulinlll.
  • Figure 5f shows LPCs stained for NeuN.
  • Figure 5h shows LPCs stained for GFAP.
  • Panels 5a, 5c, 5e, and 5g are corresponding phase contrast images.
  • Figure 6 shows Nestin (6b, 6f) and BrdU (6d, 6h) staining of neuronal-precursor-like cells arising from LPC clusters cultured in an assembled peptide structure in HGM in the presence of EGF (6a-6d) or EGF plus NGF (6e-6h).
  • 6a, 6c, 6e, and 6g are phase contrast images of 6b, 6d, 6f, and 6h.
  • Figure 7 shows the phenotype of LPC cells cultured on laminin-coated plates in
  • FIG. 7a shows cells that assumed a classical hepatocyte shape.
  • Figure 7b shows the same cells as in 7a after staining for CYPIAI activity.
  • Figure 7c shows cells that assumed a flat, expanded shape with some processes.
  • Figure 7d shows the same cells as in 7c after staining for GFAP.
  • Figure 7e shows another example of cells that assumed a flat, expanded shape with some processes.
  • Figure 7f shows the same cells as in 7e after staining for GFAP.
  • Figure 8 shows analysis of LPC cell division on conventional culture dish or after encapsulation in peptide hydrogel.
  • Figure 8a is a phase contrast micrograph showing cells immediately after encapsulation. (400X magnification).
  • Figure 8b is a phase contrast micrograph showing cells 24 hours after encapsulation. (400X magnification).
  • Figure 8c is a phase contrast micrograph showing cells 48 hours after encapsulation illustrating adoption of a spheroid morphology (approximately 5-6 cells, 400X magnification).
  • Figure 8d is a phase contrast micrograph showing cells 96 hours after encapsulation illustrating a spheroid containing approximately 10-14 cells. (400X magnification).
  • Figure 8e shows a phase contrast micrograph of a control colony grown on a conventional tissue culture dish for 48 hours. (200X magnification).
  • Figure 8f shows the same colony as in 8e immunostained for BrdU. (200X magnification).
  • Figure 8g shows a phase contrast micrograph of a spheroid colony after 96 hours of growth encapsulated in peptide hydrogel. (200X magnification).
  • Figure 8h shows the same colony as in 8g immunostained for BrdU. (200X magnification).
  • Figure 9 shows phenotypic analysis of LPC cells during exponential growth on conventional culture dish either after isolation from regular culture conditions or after isolation from peptide hydrogel culture.
  • Figure 9a is a phase contrast micrograph of a control colony.
  • Figure 9b shows the same cells as in 9a after staining for C/EPB ⁇ .
  • Figure 9c is a phase contrast micrograph of a spheroid containing cells isolated from peptide hydrogel.
  • Figure 9d shows the same cells as in 9c after staining for C/EPB ⁇ .
  • Figure 9e is a phase contrast micrograph of a control colony.
  • Figure 9f shows the same cells as in 9e after staining for albumin.
  • Figure 9g is a phase contrast micrograph of a spheroid containing cells isolated from peptide hydrogel.
  • Figure 9h shows the same cells as in 9g after staining for albumin.
  • Figure 9i is a phase contrast micrograph of a control colony.
  • Figure 9j shows the same cells as in 9g after staining for CYP1A1/1A2.
  • Figure 9k is a phase contrast micrograph of a spheroid containing cells isolated from peptide hydrogel.
  • Figure 91 shows the same cells as in 9g after staining for CYP1A1/1A2.
  • Figure 10 shows induction of CYPIAI and CYP1A2 activities by 3- methylcholanthrene (3-MC) in LPC control cultures and hydrogel derived LPC spheroid colonies. Units of activity are expressed as picomoles/cell hour and the data correspond to the average value from triplicates and their standard deviation (SD).
  • SD standard deviation
  • CYP activity is presented with circles in non induced (-3-MC) cultures, and with squares in induced (+3-MC) cultures. The arrow in each panel indicates the time at which the inducer 3-MC was added to the cultures.
  • Figure 10a shows CYPIAI activity measured in LPC control cultures.
  • Figure 10b shows CYP1A2 activity measured in hydrogel derived LPC spheroid colonies.
  • Figure 10c shows CYPIAI activity measured in LPC control cultures.
  • Figure lOd shows CYP1 A2 activity measured in hydrogel derived LPC spheroid colonies.
  • Figure 11 compares LPC spheroids growing in peptide hydrogels in the absence or presence of ECM components.
  • Figures 11a and 1 lb show phase contrast micrographs of LPC spheroids growing in peptide hydrogels in the absence of ECM components and growth factors. Bars represent 1Q0 ⁇ m in length.
  • Figures lie and lid show phase contrast micrographs of LPC spheroids formed by cells grown in the presence of laminin, EGF, and FGF-2. Bars represent 100 ⁇ m in length.
  • Figure 12 shows immuno fluorescence staining for insulin in hydrogel derived LPC colonies cultured under various conditions.
  • Figure 12a is a phase contrast micrograph of a control colony obtained after 8 days of culture in peptide hydrogel followed by overnight culture on a regular plastic culture dish.
  • Figure 12b shows the same optical layer as Figure 12a after staining for insulin.
  • Figure 12c is a phase contrast micrograph of a colony obtained after 8 days of culture in peptide hydrogel with 50 ⁇ g/ml fibronectin and 0.8 ng/ml EGF followed by overnight culture on a regular plastic culture dish.
  • Figure 12d shows the same optical layer as Figure 12c after staining for insulin.
  • Figure 12e is a phase contrast micrograph of a colony obtained after 8 days of culture in peptide hydrogel with 50 ⁇ g/ml laminin-1, 0.8 ng/ml EGF, and 0.5 ng/ml FGF-2 followed by overnight culture on a regular plastic culture dish.
  • Figure 12f shows the same optical layer as in Figure 12e after staining for insulin.
  • Figure 13 is a chart comparing insulin release by hydrogel-derived spheroids cultured according to a pancreatic differentiation protocol following stimulation by various stimulating conditions.
  • Stem cells have been defined as cells that are able to both self-renew, i.e., to divide and create additional stem cells, and also to give rise to cells that can undergo differentiation along a specified pathway or pathways (See, e.g., Fuchs, E. and Segre, J., "Stem Cells: A New Lease on Life", Cell, 100, 143-155, 2000; Weissman, I., “Stem Cells: Units of Development, Units of Regeneration, and Units in Evolution", Cell, 100, 157-168, 2000).
  • stem cells themselves are undifferentiated but are able to generate one or more specialized cell types with specific functions in the body.
  • Differentiation refers to a qualitative change in cellular phenotype that is the consequence of the synthesis of new gene products (Loeffler, M. and Potten, C, "Stem cells and cellular pedigrees - a conceptual introduction", in Stem Cells, Potten, C. (ed.), Academic Press, San Diego, 1997).
  • Differentiation or transdifferentiation may be recognized by a morphological change in the cell or by detecting changes in enzyme activity or protein composition.
  • Proteins (including enzymes) and the mRNAs that encode such proteins that may be used to characterize a particular differentiation pathway or state are referred to herein as markers. Such markers may not be unique to a particular differentiated
  • 35S3475 14 ° f l 0 ° cell type but may be found in a variety of differentiated cell types.
  • cytochrome P450 enzymes are produced by mature hepatocytes and are thus markers for hepatocyte differentiation.
  • some of these enzymes are also produced by cells in the intestine and are thus also markers for these intestinal cells.
  • One of ordinary skill in the art will readily be able to select an appropriate marker or combination of markers that are sufficient to identify a cell as being of a particular differentiated cell type.
  • Embryonic stem cells present in the embryonic blastocyst, are sufficiently undifferentiated that they are able to give rise to any cell type. Somatic stem cells are found in specific adult tissues, where they are thought to be able to divide indefinitely. Until recently it was widely believed that somatic stem cells possessed a restricted in vivo differentiation capability, e.g., that they were only able to give rise to differentiated cells characteristic of the tissues in which they were found. Recent results, however, have suggested that somatic stem cells may have a much broader range of differentiation possibilities than previously thought.
  • neural stem cells appear able to give rise to hematopoietic cells in vivo (Bjornson, C, et al, Science, 283:534-537), while hematopoietic stem cells can differentiate into hepatocytes (Lagasse, E., et al, "Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nature Medicine, 6:1229-1234, 2000).
  • progenitor cell refers to a cell that is not fully differentiated but that has the capacity to give rise to a daughter cell or cells that are able to do so.
  • a stem cell is one type of pro genitor cell.
  • a stem cell is generally considered to have broader differentiation potential than other types of progenitor cells.
  • Stem cells are generally considered to have the ability to self-renew.
  • progenitor cell also includes cells that may have undertaken one or more steps along a differentiation pathway, e.g., that express one or more differentiation markers.
  • precursor cell and “progenitor cell” are used interchangeably herein.
  • stem cell is understood to refer to either adult stem cells, e.g., liver stem cells, or embryonic stem cells.
  • transdifferentiation refers to (1) the capacity of a progenitor cell isolated from a particular body tissue or organ, either to differentiate into cells of a type normally found in a different body tissue or organ or to give rise to a daughter cell or cells that are able to do so or (2) the capacity of a cell that exhibits a cellular morphology characteristic of a particular cell lineage or expresses one or more differentiation markers characteristic of a particular cell lineage to alter its developmental fate and to adopt an alternate differentiation pathway.
  • cellular reprogramming Altering the differentiation or transdifferentiation potential of a cell may be referred to as cellular reprogramming, which may also include inducing a cell that has exited the cell cycle, e.g., a post-mitotic cell, to re-enter the cell cycle.
  • Agents that enhance or stimulate transdifferentiation, and/or cell cycle reentry may be referred to as reprogramming agents.
  • compositions and methods for manipulating the extracellular environment of a progenitor cell or stem cell including compositions and methods for enhancing differentiation and transdifferentiation.
  • Such compositions and methods include growing cells under physical conditions that render the cells permissive for instruction along particular differentiation pathways.
  • the physical conditions can include, in particular, encapsulating progenitor cells within three-dimensional peptide hydrogels.
  • the instruction can comprise exposing the cells to one or more growth or differentiation factors and/or one or more extracellular matrix (ECM) components, h preferred embodiments of the invention at least part of the exposure occurs while the cells are cultured within a three-dimensional nanoscale material such as a peptide hydrogel as described herein.
  • ECM extracellular matrix
  • compositions and methods of the present invention allow harnessing of the inherent regenerative capacity of progenitor cells in new and useful ways.
  • the regenerative capacity of the body is particularly striking in the case of certain organs such as the liver, which is well-known to possess extensive capacity to regenerate after insults ranging from partial hepatectomy to toxin-induced injury.
  • liver regeneration is thought not to depend on a small group of progenitor cells. Instead, regeneration occurs through the division of mature cell populations including hepatocytes (the main functional cells of the liver, which synthesize a wide range of proteins including enzymes that serve key roles in metabolism of exogenous and endogenous compounds); biliary epithelial cells (which line biliary ducts); endothelial cells; Kupffer cells (macrophages); and stellate cells, also referred to as Ito cells (which are located under liver sinusoids, surround hepatocytes with long processes, and secrete extracellular matrix proteins and growth factors). Liver regeneration is extensively reviewed in Michalopoulos, G. and DeFrances, M., "Liver Regeneration", Science, 276, 60-66, 1997.
  • liver-derived cells tend to lose certain aspects of the mature hepatocyte phenotype. This feature has hampered the development of cell culture systems in which to study hepatotropic viruses such as hepatitis B virus, which replicate in mature hepatocytes. In addition, it limits the utility of liver-derived cells in medical applications such as tissue engineering (e.g., artificial livers), cell transplantation therapies, and gene therapy.
  • the liver Unlike the central nervous system, the liver represents an organ that is readily accessible for the removal of tissue.
  • the present invention represents a convergence of research in the fields of stem and progenitor cell biology and technology and research in the field of biological materials.
  • peptide structures are able to support cell attachment, viability, and growth when cells are cultured on the surface of the structure, h addition, the structures (also referred to herein as scaffolds) are able to serve as substrates for neurite outgrowth and synapse formation when neurons are grown on their surface (Holmes, T., et al, Proc. Natl. Acad. Sci., 97(12), 2000).
  • the structures also referred to herein as scaffolds
  • Somatic cells were isolated from liver (see Example 1) and cultured in three dimensional peptide structures (peptide hydrogels) in various media and in the presence of different growth factor(s). Because of the cellular plasticity exhibited by these cells, they are referred to as "liver progenitor cells" (LPCs).
  • LPCs liver progenitor cells
  • the name LPC was chosen to indicate the tissue of origin, while not restricting expectations for their differentiation and/or self-renewal potential.
  • the peptide hydrogel structures are described in further detail below. As presented in more detail in the Examples, the peptide hydrogel provided an environment that altered the phenotypes and differentiation pathways adopted by cells cultured therein.
  • rat liver progenitor cells when cultured on traditional plastic culture dishes, rat liver progenitor cells maintain a uniform, flat morphology and do not differentiate well into functional hepatocytes. Such cells fail to express significant amounts of cytochromes P4501A1 (CYPIAI) or P4501A2 (CYP1A2), enzymes produced by mature hepatocytes.
  • cytochromes P4501A1 CYPIAI
  • P4501A2 CYP1A2
  • rat liver progenitor cells cultured in a three-dimensional peptide hydrogel divide to form spheroidal clusters, reminiscent of the behavior of mature hepatocytes under certain culture conditions.
  • a portion of cells maintained in the hydrogels express CYPIAI and/or CYP1A2 and display CYPIAI and CYP1A2 enzymatic activity such as CYPIAI and CYPl A2-dependent 0-dealkylation activities on a resorufin alkyl ether substrate (7-ethoxyresorufin and 7-methoxyresofurin, respectively), and ability to catalyze 3- N-demethylation of the caffeine (1,3,7-trimethylxanthine) to produce paraxanthine (1,7-dimethylxanthine) (a CYPlA2-specific metabolic activity).
  • 3583475V1 2 ° ° f l 0 ° cultured within the peptide hydrogel structure exhibited the ability to differentiate along a hepatocyte-like lineage and to transdifferentiate along a neuronal lineage.
  • Cells grown in soft agar did not proliferate or exhibit either hepatocyte-like or neuronal-like phenotypes, suggesting that the mere arrangement of the cells in three dimensions is not sufficient to allow these effects.
  • Liver and ventral pancreas appear to arise from the same cell population within the embryonic endodenn (Sell, S. and flic, Z., Liver Stem Cells, Chapman and Hall, New York, 1997). Studies have demonstrated the possible existence of a bipotential precursor population for pancreas and liver during mammalian embryonic development (Deutsch, G. et al, Development 128, 871-881, 2001).
  • pancreas cells may originate from a common lineage, adult liver stem cells could be stimulated to differentiate into pancreatic lineage cells of one or more types.
  • Pancreatic tissue comprises both exocrine and endocrine cell types. It is believed that all endocrine cells of the pancreatic islets of Langerhans, including glucagon-producing ⁇ cells, insulin-producing ⁇ cells, pancreatic polypeptide producing ⁇ cells, and somatostatin producing ⁇ cells originate from the same ductal epithelial stem cells through sequential differentiation.
  • Pancreatic exocrine cells secrete a number of digestive enzymes including trypsin, chymotrypsin, elastase, lipases, amylase, etc., in addition to secreting bicarbonate.
  • Pancreatic cell types can be identified by their expression of genes encoding these polypeptide products and also by their expression of a variety of other markers.
  • pancreatic lineage-like cells 3583475vl pancreatic lineage-like cells.
  • a three-dimensional nanoscale environment comprising a peptide hydrogel is able to support the growth and differentiation of cells having properties of liver cell precursors, liver stem cells, hepatocytes, and oval cells, hi addition, the hydrogel is able to support the growth, trans-differentiation, and differentiation of cells having properties of neural lineage cells. Furthermore, the hydrogel environment is able to support the growth and functional activity of cells having properties of endocrine cells such as ⁇ -like insulin producing pancreatic cells. Cell types such as these exist in a wide variety of three- dimensional environments within the body.
  • the hydrogel is able to support the growth, trans-differentiation, and/or differentiation of a wide range of cell types, e.g., cell types that may exist in a variety of different three-dimensional environments within the body.
  • the hydrogel provides an environment conducive to the differentiation or transdifferentiation of liver progenitor cells into a variety of different cell types.
  • Such cell types include cells of liver tissue origin including cells that functionally and morphologically resemble mature hepatocytes, cells of neural tissue origin, and cells of pancreatic origin including insulin producing ⁇ -like cells.
  • the invention thus provides a composition comprising a peptide hydrogel structure encapsulating progenitor cells and a differentiation or transdifferentiation enhancing factor such as an ECM component or growth factor, which may be present or added to medium in which the structure is cultured.
  • the progenitor cell is a liver progenitor cell, i.e., a cell that does not express a fully differentiated liver-specific phenotype but that has the capacity, under appropriate conditions, to give rise to cells that assume a liver- specific cellular morphology and/or express a marker characteristic of a liver- specific cell.
  • the liver progenitor cell is a liver progenitor cell, i.e., a cell that does not express a fully differentiated liver-specific phenotype but that has the capacity, under appropriate conditions, to give rise to cells that assume a liver- specific cellular morphology and/or express a marker characteristic of a liver- specific cell.
  • the liver progenitor cell is
  • the liver progenitor cell may be isolated from another organ, e.g., from the bone marrow.
  • the invention further provides methods for enhancing cellular differentiation and transdifferentiation comprising encapsulating a progenitor cell within a peptide hydrogel structure and culturing the encapsulated cells in the presence of one or more differentiation or transdifferentiation enhancing factors such as a growth factor or ECM component for a time sufficient to allow differentiation or transdifferentiation to occur, h certain embodiments of the invention the progenitor cell is a liver progenitor cell.
  • the process of differentiation or transdifferentiation may occur within the cell or within progeny or descendants of the cell.
  • the differentiation may be along a liver-specific lineage pathway, e.g., towards a hepatocyte-like phenotype.
  • the transdifferentiation may be along a neuronal-like pathway, e.g., towards a neuronal precursor, a neuron, or a glial cell.
  • the transdifferentiation may be along a pancreatic-like lineage pathway, e.g., towards a pancreatic endocrine cell such as a ⁇ cell or an exocrine cell. Both transdifferentiation and differentiation may occur among the progeny of the encapsulated cells, and different cells within the peptide structure may transdifferentiate along different lineage pathways.
  • peptide sequence, length, and concentration may be varied, which may in turn affect the stiffness, oxygen tension, fraction of cell surface in contact with the gel, and/or growth factor gradients within the structure.
  • the particular growth factor(s) and ECM components may be varied as may their concentrations. All such improvements and refinements are within the scope of the invention.
  • 3583475vl structures in order to achieve various effects on cell division and phenotype.
  • Methods for monitoring the effects of the peptide structures and culture conditions on cell division and phenotype are also presented.
  • an in vitro culture system for studying stem and progenitor cells and their differentiation and transdifferentiation properties
  • an in vitro culture system for growing hepatocyte- like cells and/or mature hepatocytes, which may be used, for example, to propagate hepatotropic viruses
  • a system for controlling and manipulating cell differentiation and transdifferentiation in vitro from which cells can be extracted and then either maintained in vitro or administered to a subject
  • an in vitro culture system for testing the toxicity of compounds and evaluating their metabolism, biotransformation, etc.
  • a system for controlling and manipulating cell differentiation and transdifferentiation in vitro within a structure that is to be implanted within a subject e.g., for treating a disorder or disease.
  • Various other embodiments of the invention such as cell culture kits and assay systems are also described.
  • peptides consisting of alternating hydrophilic and hydrophobic amino acids that are capable of self-assembling to form an exceedingly stable beta-sheet macroscopic structure in the presence of electrolytes, such as monovalent cations.
  • the peptides are complementary and structurally compatible. These peptides and their properties are described in U.S. Patent Numbers 5,955,343 and 5,670,483 and in co-pending U.S. Patent Application Serial No. 09/778200, filed February 6, 2001, entitled "Peptide Scaffold Encapsulation Of Tissue Cells And Uses Thereof.
  • NaCl at a concentration of between 5 mM and 5 M induces the assembly of macroscopic structures within a few minutes.
  • the side-chains of the peptides in the structure partition into two faces, a polar face with charged ionic side chains and a nonpolar face with alanines or other hydrophobic groups. These ionic side chains are self-complementary to one another in that the positively charged and negatively
  • 3583475vl charged amino acid residues can form complementary ionic pairs. These peptides are therefore called ionic, self-complementary peptides, or Type I self-assembling peptides. If the ionic residues alternate with one positively and one negatively charged residue(- + - + -+ - +), the peptides are described as "modulus I;” if the ionic residues alternate with two positively and two negatively charged residues (- - + + + - - ++), the peptides are described as "modulus II.”
  • modulus I and II self-complementary peptides with identical compositions and length have been analyzed previously (Table 1).
  • Modulus TV ionic self-complementary peptides containing 16 amino acids such as EAK16-IV, KAE16-IV, DAR16-IV and RAD16-1N; has also been studied. If the charged residues in these self-assembling peptides are substituted (i. e., the positive charged lysines are replaced by positively charged arginines and the negatively charged glutamates are replaced by negatively charged aspartates), there are essentially no significant effects on the self-assembly process.
  • the peptides can no longer undergo self-assembly to form macroscopic structures; however, they can still form a beta-sheet structure in the presence of salt.
  • Other hydrophilic residues, such as asparagine and glutamine, that form hydrogen-bonds may be incorporated into the peptides instead of or in addition to charged residues.
  • alanines in the peptides are changed to more hydrophobic residues, such as leucine, isoleucine, phenylalanine or tyrosine, these peptides have a greater tendency to self-assemble and form peptide matrices with enhanced strength.
  • Some peptides that have similar compositions and lengths as these aforementioned peptides form alpha-helices and random-coils rather than beta-sheets and do not form macroscopic structures.
  • other factors are likely to be important for the formation of macroscopic structures, such as the peptide length, the degree of intermolecular interaction, and the ability to form staggered arrays.
  • N/A denotes not applicable * These peptides form a ⁇ -sheet when incubated in a solution containing NaCl, however they have not been observed to self-assemble to form macroscopic scaffolds.
  • Other self-assembling peptides may be generated by changing the amino acid sequence of any self-assembling peptide by a single amino acid residue or by multiple amino acid residues.
  • the incorporation of specific cell recognition ligands, such as RGD and RAD, into the peptide scaffold may promote the proliferation of the encapsulated cells. In vivo these ligands may also attract cells from outside a scaffold to the scaffold, where they may invade the scaffold or otherwise interact with the encapsulated cells.
  • cysteines may be incorporated into the peptides to allow the formation of disulfide bonds, or residues with aromatic rings maybe incorporated and cross-linked by exposure to UV light.
  • the in vivo half-life of the scaffolds may also be modulated by the incorporation of protease cleavage sites into the scaffold, allowing the scaffold to be enzymatically degraded. Combinations of any of the above alterations may also be made to the same peptide structure.
  • Peptides capable of being cross-linked may be synthesized using standard f-moc chemistry and purified using high pressure liquid chromatography. The formation of a peptide structure maybe initiated by the addition of electrolytes as described herein. Hydrophobic residues with aromatic side chains may be crossed- linked by exposure to UV irradiation. The extent of the cross-linking may be precisely controlled by the predetermined length of exposure to UV light and the predetermined peptide concentration. The extent of cross-linking may be determined by light scattering, gel filtration, or scanning electron microscopy using standard methods. Furthermore, the extent of cross-linking may also be examined by HPLC or mass spectrometry analysis of the scaffold after digestion with a
  • the material strength of the scaffold may be determined before and after cross-linking.
  • Aggrecan processing sites may be added to the amino- or carboxy-terminus of the peptides or between the amino-and carboxy- termini.
  • MMPs matrix metalloproteases
  • Peptide structures formed from these peptides, alone or in combination with peptides capable of being cross-linked, may be exposed to various protease for various lengths of time and at various protease and scaffold concentrations. The rate of degradation of the scaffolds may be determined by HPLC, mass spectrometry, or NMR analysis of the digested peptides released into the supernatantat various time points.
  • radiolabeled peptides are used for scaffold formation, the amount of radiolabeled peptides released into the supernatant maybe measured by scintillation counting.
  • Cross-linking and cleavage studies are described further in pending U.S. Patent Application Serial No. 09/778200, filed February 6, 2001 , Entitled "Peptide Scaffold Encapsulation Of Tissue Cells And Uses Thereof.
  • the peptide scaffolds formed from any of the above peptides may be characterized using various biophysical and optical instrumentation, such as circular dichroism (CD), dynamic light scattering, Fourier transform infrared (FTLR), atomic force microscopy (ATM), scaiming electron microscopy (SEM),and transmission electron microscopy (TEM).
  • biophysical methods may be used to determine the degree of beta-sheet secondary structure in the peptide structure.
  • filament and pore size, fiber diameter, length, elasticity, and volume fraction may be determined using quantitative image analysis of scanning and transmission electron microscopy.
  • the structures may also be examined using several standard mechanical testing techniques to measure the extent of swelling, the effect of pH and electrolyte concentration on structure formation, the level of hydration under various conditions, and the tensile strength.
  • the peptide hydrogels described herein are significantly different from other biopolymer-based biomaterials for several reasons. Most biomaterials have fiber sizes diameters generally in the 10-20 micron range (microscale), similar in scale to the size of many types of cells. When grown in an environment comprising such
  • 3583475V1 28 ⁇ f 100 microscale fibers cells attach to the microfiber with a curvature.
  • Cells grown in a typical biopolymer-based biomaterial are also less hydrated than when grown in the nanoscale environment created by the self-assembling peptide hydrogels described herein.
  • the self-assembling peptides described herein are approximately 5 mn in length and approximately 1 nm in diameter. Such peptides undergo self-assembly to form nanofibers (e.g., fibers having a diameter of approximately 10-20 nm). While not wishing to be bound by any theory, inventors suggest that in such an environment cells truly experience three dimensional spatial enclosures on a scale that is relevant to cellular dimensions.
  • the peptides undergo self-assembly to form nanofibers that are highly hydrated (e.g., up to 99.5-99.9%% (1-5 mg/ml) water). Because the hydrogel has such an extremely high water content, cells can freely migrate and form intercellular contacts and structures such as the spheroids described herein. Such environment also permits diffusion of small molecules including proteins and signaling molecule exchanges.
  • Peptide structures may be generated in a variety of shapes and geometries by forming the structure within an appropriately shaped mold. Where the peptide structure or scaffold is to be implanted into the body, the shape may be selected based upon the intended implantation site, for example.
  • a peptide structure peptides and living cells may be incubated in an aqueous solution having an iso-osmotic solute (i.e., a solute at an appropriate concentration to support cell viability), under conditions that do not allow the peptides to substantially self-assemble.
  • the solution contains less than 10, 5, 1, or 0.1 mM electrolyte or is substantially free of electrolyte.
  • the concentration of the added electrolyte is at least 5, 10, 20, or 50 mM.
  • Suitable electrolytes include, but are not limited to, Li + , Na + , K + , and Cs + .
  • the concentration of the iso-osmotic solute is at least 50, 150, or 300
  • the concentration of the iso-osmotic solute is contained in one of the following ranges 200 to 250 mM, 250 to 270 mM, 270 to 300 mM, 300 to 400 mM, 400 to 500 mM, 500 to 600 mM, 600 to 700 mM, 700 to 800 mM, or 800 to 900 mM, inclusive.
  • Suitable iso-osmotic solutes include, but are not limited to, carbohydrates, such as sucrose, mannitol, etc.
  • Other iso-osmotic solutes, preferably non-toxic to cells at the concentration used, may be employed.
  • peptides and living cells may be incubated in an aqueous solution having an iso- osmotic solute, under conditions that do not allow the peptides to substantially self- assemble.
  • the solution contains less than 10, 5, 1, or 0.1 mM electrolyte or is substantially free of electrolytes.
  • the solution is contained in a pre-shaped mold dimensioned to determine the volume or shape of the macroscopic structure. Sufficient electrolyte is added to the solution to initiate self-assembly of the peptides into a beta-sheet macroscopic structure, whereby the cells are encapsulated by the formation of the macroscopic structure.
  • the encapsulated cells are present in the structure in a three-dimensional arrangement.
  • the concentration of the added electrolyte may be at least 5, 10, 20, or 50 mM. Suitable electrolytes include Li + , Na + , K + , and Cs + .
  • the concentration of the iso-osmotic solute is at least 50, 150, or 300 mM. In another embodiment, the concentration of the iso-osmotic solute is contained in one of the following ranges 200 to 250 mM, 250 to 270 mM, 270 to 300 mM, 300 to 400 mM, 400 to 500 mM, 500 to 600 mM, 600 to 700 mM, 700 to 800 mM, or800 to 900 mM, inclusive.
  • Suitable iso-osmotic solutes include, but are not limited to, carbohydrates such as sucrose, etc.
  • the peptide structures may be used for regenerating a tissue, and the invention includes methods for such use.
  • the methods includes administering to an animal, such as a mammal (including a human) a macroscopic scaffold structure having amphiphilic peptides and encapsulated living progenitor cells and/or their progeny.
  • the peptides have alternating hydrophobic and hydrophilic amino acids, are complementary and structurally compatible, self-assemble into a beta-sheet macroscopic structure and render the progenitor cells or their progeny permissive for instruction to differentiate and/or transdifferentiate.
  • the encapsulated cells are present in the macroscopic structure in a three- dimensional arrangement.
  • the density of the cells maybe approximately 10 5 /ml, between 5 x 10 5 /ml and 5 x 10 6 /ml, inclusive, between 5 x 10 4 /ml and 5 x 10 5 /ml, between 5 x 10 5 /ml and 5 x 10 6 /ml. Other ranges may also be used.
  • Conditions for culturing should be close to physiological conditions.
  • the pH of the culture medium should be close to physiological pH, preferably between pH 6-8, for example about pH 7 to 7.8, in particular pH 7.4.
  • Physiological temperatures range between about 30° C to 40°C.
  • Mammalian cells are preferably cultured at temperatures between about 32° C to about 38°C, e.g., between about 35° C to about 37° C.
  • Cells may be cultured within the peptide scaffold for any appropriate time, depending upon the cell number and density desired, the proliferation rate of the cells, and the time required for the desired differentation and/or transdifferentiation to occur. These parameters will vary depending upon the particular progenitor cells and purposes for which the invention is to be used. One of ordinary skill in the art will be able to vary these parameters and to observe the effects of doing so, in order to determine the optimal time for maintaining cells in culture within the scaffold. In certain embodiments of the invention the cell are cultured for approximately 3 days, 7 days, 14 days, 21 days, 28 days, 56 days, or 90 days.
  • the cells are cultured for between 1 and 3 days inclusive, between 4 and 7 days inclusive, between 8 and 14 days inclusive, between 15 and 21 days inclusive, between 22 and 28 days inclusive, between 29 and 56 days inclusive, or between 57 and 90 days inclusive. Longer or shorter culture periods may also be used.
  • the peptide scaffold encapsulating cells may be used to treat a variety of tissue defects, including nervous tissue defects, liver defects, pancreatic tissue defects, connective tissue defects, etc. Cell types that may be used are described further below.
  • the peptide hydrogel structure may be implanted into the body, e.g., surgically or using any other type of suitable procedure. Other routes, including oral, percutaneous, intramuscular, intravenous, and subcutaneous may be employed. One of ordinary skill in the art will be able to select an appropriate delivery technique.
  • the macroscopic structure may assemble prior to admimstration, but in
  • the progenitor cells and peptides are mixed in vitro and the structure self-assembles after administration and encapsulates the cells in vivo.
  • the administered solution contains less than 10, 5, 1.0, or 0.1 mM electrolyte or is substantially free of electrolyte, and the concentration of the iso-osmotic solute is at least 50, 150, or 300 mM.
  • the concentration of iso-osmotic solute is contained in one of the following ranges 200 to 250 mM, 250 to 270 mM, 270 to 300 mM, 300 to 400 mM, 400 to 500 mM, 500to 600 mM, 600 to 700 mM, 700 to 800 mM, or 800 to 900 mM, inclusive.
  • Suitable iso-osmotic solutes include, but are not limited to, carbohydrates, such as sucrose.
  • the macroscopic scaffold structure is enzymatically degradable.
  • the macroscopic scaffold is cleavable by a metalloprotease, collagenase, or aggrecanase in vivo or in vitro.
  • the macroscopic structure further encapsulates a therapeutically active compound or chemoattractant.
  • a therapeutically active compound or chemoattractant examples include synthetic organic molecules, naturally occurring organic molecules, nucleic acid molecules, biosynthetic proteins such as chemokines, or modified naturally occurring proteins.
  • the macroscopic structure further encapsulates one or more growth enhancing, differentiation- enhancing, or transdifferentiating-enhancing agents, e.g., growth factors, such as epidermal growth factor, nerve growth factor, transforming growth factor- ⁇ , platelet-derived growth factor, insulin-like growth factor, acidic fibroblast growth factor, basic fibroblast growth factor, hepatocyte growth factor, brain-derived neurotrophic factor, keratinocyte growth factor, bone morphogenetic protein, or a cartilage-derived growth factor. Combinations of growth factors and/or therapeutic agents or chemoattractants may be used.
  • growth factors such as epidermal growth factor, nerve growth factor, transforming growth factor- ⁇ , platelet-derived growth factor, insulin-like growth factor, acidic fibroblast growth factor, basic fibroblast growth factor, hepatocyte growth factor, brain-derived neurotrophic factor, keratinocyte growth factor, bone morphogenetic protein, or a cartilage-derived growth factor.
  • growth factors such as epidermal growth factor, nerve growth
  • the macroscopic structure contains one or more extracellular matrix (ECM) components.
  • ECM extracellular matrix
  • the extracellular matrix includes proteins that are secreted locally and are widely distributed.
  • the major types of proteins that constitute the ECM include collagens, elastin, fibronectin, and laminin.
  • the dermis contains ground substance, cellular components including
  • proteinaceous components of the ECM consist largely of collagen (Type I collagen) and reticulin (Type III collagen), which fonn fibers that help to provide tensile strength.
  • Elastic fibers provide for restoration of shape after a deformation.
  • Ground substance, which undergoes constant turnover (synthesis and degradation) consists largely of glycosaminoglycans, e.g., hyaluronic acid, chondroitin sulfate, and dermatan sulfate.
  • Collagens are a family of highly characteristic fibrous proteins believed to be present in all multicellular animals. They are the most abundant proteins in mammals, constituting approximately one quarter of total protein. A primary feature of all known collagen molecules is their triple-stranded helical structure. See, for example, Miller and Gay, "The Collagens: An Overview and Update,” pp. 3-41, Methods in Enzymology (ed. Colowick and Kaplan), v. 144 (1987), Academic Press, Inc.
  • Elastin present in elastic fibers of certain tissues such as blood vessels and skin, gives such tissues the required ability to recoil after transient stretch.
  • Elastin is the major component of these elastic fibers, where it is present as an extensively cross-linked polypeptide having a particular chemical composition. Approximately one third of the amino acids in elastin are glycine, 10-13 percent are pro line, and over 40 percent are other amino acids with hydrophobic side chains. Elastin contains very small amounts of hydrophilic amino acids.
  • Laminin a large glycoprotein and a major component of basement membranes, is made by all epithelial cells studied thus far. Laminin consists of three different subunits disulfide-bonded to form an asymmetric cross-linked structure. For a review see Barlow et al, "Molecular Cloning of Laminin," pp. 404-474 in Methods in Enzymology, v. 144 (1987) Academic Press, Inc.
  • Fibronectin is a cell-surface and blood glycoprotein involved in a variety of cell surface phenomena. It occurs as an insoluble form at the cell surface and in connective tissue. Fibronectin is also found in soluble form in plasma.
  • ECM molecules are described in Kreis, T. (ed.) Guidebook to the Extracellular Matrix, Anchor, and Adhesion Proteins, 2 n Ed., Oxford University Press, 1999; Streuli, C, et al., Extracellular Matrix Protocols (Methods in Molecular Biology, v. 139), Totowa, NJ, Humana Press, 2000 and references therein.
  • ECM components serve a variety of functions in the cellular environment, hi addition to serving a structural role, they are likely to be involved in cell signalling and cell communication. ECM components influence cellular access to nutrients, metabolites, growth factors, and chemokines and thus exert a significant influence on cell proliferation and differentiation.
  • Growth-enhancing, differentiation-enhancing, and/or transdifferentiation- enhancing agents may be added to the peptide solution or to the electrolyte solution prior to initiation of self-assembly. In this case the concentration of the agent will likely be substantially uniform within the assembled scaffold.
  • the agent is added to media with which the peptide scaffold is incubated after encapsulation of cells. After addition to the media, a portion of the differentiation-enhancing agent enters the peptide scaffold, e.g., through diffusion. This process may create a gradient of the differentiation- enhancing factor. Cells in different regions of the scaffold may exhibit different responses to the agent depending upon the concentration of the agent at the location of the cell.
  • the peptide structure renders the encapsulated cells permissive to instruction by the differentiation-enhancing or transdifferentiation-enhancing agent.
  • encapsulated progenitor cells and/or their progeny are induced to differentiate and/or transdifferentiate in the presence of the agent.
  • Growth factors are typically used at concentrations ranging between about 1 fg/ml to 1 mg/ml. Frequently growth factors are used at concentrations in the low nanomolar range, e.g., 1 - 10 nM.
  • growth factors are used at concentrations that are not typically used in the prior art or that are not typically found in vivo under normal conditions.
  • growth factors may be used at concentrations that are 5 fold greater, 10 fold greater, 20 fold greater, 100 fold greater, etc., than is typically required to produce effects or than typically occurs in vivo.
  • Titration experiments can be performed to determine the optimal concentration of a particular differentiation-enhancing agents, such as a growth factor, depending upon the particular growth, differentiating, and/or transdifferentiating effects desired.
  • ECM components will typically be provided at concentrations in the range of ⁇ g/ml, e.g., between 5 and 1000 ⁇ g/ml, more typically in ranges of approximately 10 to 100 ⁇ g/ml. However, higher or lower concentrations can also be used, e.g., in the micromolar or nanomolar range.
  • the peptides that assemble to form a macroscopic structure have a sequence that includes an adhesion site, growth factor binding site, or sequence that provides targeting to a cell, tissue, organ, organ system, or site within an animal.
  • peptides forming the macroscopic scaffold contain between 8 and 200 amino acids, 8 to 36 amino acids, or 8 to 16 amino acids, inclusive.
  • concentration of the peptides is between 1 and 10 mg/ml or between 4 and 8 mg/ml, inclusive.
  • organs or body structures include, but are not necessarily limited to, brain, nervous tissue, esophagus, fallopian tube, heart, intestines, gallbladder, kidney, liver, lung, ovaries, pancreas, prostate, bladder, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, ureter, urethra, and uterus.
  • progenitor cells and/or their progeny that have proliferated, differentiated, and/or transdifferentiated within the peptide scaffold are extracted from the scaffold.
  • the extraction may be accomplished by any suitable means, including mechanical disruption of the scaffold, enzymatic degradation of the scaffold in vitro, etc.
  • 3583475vl method selected results in extraction of approximately 25%, between 25% and 50% of the cells inclusive, between 51% and 75 % of the cells inclusive, or between 76% and 100%) of the cells inclusive.
  • the method selected may depend upon the purposes for which the cells are to be used, the number of cells required, etc.
  • the viability of the extracted cells is approximately 10%) of cells, between 10%> and 25% inclusive, between 26%> and 50% of cells inclusive, between 51 and 75% of cells, inclusive, or between 76%> and 100%> of cells inclusive.
  • the method selected may depend upon the purposes for which the cells are to be used, the number of cells required, etc.
  • the extracted cells may be further cultured in vitro, either in a peptide hydrogel structure or in any other culture vessel.
  • the extracted cells may be administered to a subject by any appropriate route, including intravenous, subcutaneous, oral, percutaneous, intramuscular, or surgical.
  • the administered cells may be used to fill or repair a tissue defect or otherwise supplement an organ or body structure.
  • the administered cells may synthesize or otherwise supply a therapeutic agent.
  • the administered cells may supply a protein, e.g., an enzyme, that the individual lacks.
  • the administered cells may be genetically modified and thus used as a means to deliver gene therapy.
  • the beta-sheet secondary structure of the scaffold may be confirmed using standard circular dichroism to detect an absorbance minimum at approximately 218 nm and a maximum at approximately 195 nm.
  • the scaffold is formed from the self-assembly of peptides that may include L- amino acids, D-amino acids, natural amino acids, non-natural amino acids, or a combination thereof. If L- amino acids are present in the scaffold, degradation of the scaffold produces amino acids which may be reused by the host tissue. It is also contemplated that the peptides may be covalently linked to a compound, such as a chemoattractant or a therapeutically active compound.
  • the peptides may be chemically synthesized or purified from natural or recombinant sources, and the amino- and carboxy-termini of the peptides may be protected or not protected.
  • the peptide scaffold may be formed
  • 3583475V1 36 ⁇ f l 0 ° from one or more distinct molecular species of peptides which are complementary and structurally compatible with each other.
  • Peptides containing mismatched pairs such as the repulsive pairing of two similarly charged residues from adjacent peptides, may also fonn scaffolds if the disruptive force is dominated by stabilizing interactions between the peptides.
  • Scaffolds are also referred to herein as peptide structures, peptide hydrogel structures, peptide gel structures, or hydrogel structures.
  • the invention also includes growing progenitor cells and their progeny on the surface of peptide hydrogel scaffolds, wherein the peptide scaffold renders the progenitor cells and/or their progeny permissive for instruction by differentiation- enhancing agents.
  • “complementary” is meant the capable of forming ionic or hydrogen bonding interactions between hydrophilic residues from adjacent peptides in the scaffold, as illustrated in Fig.
  • each hydrophilic residue in a peptide either hydrogen bonds or ionically pairs with a hydrophilic residue on an adjacent peptide or is exposed to solvent.
  • structurally compatible is meant capable of maintaining a sufficiently constant intrapeptide distance to allow scaffold formation, hi certain embodiments of the invention the variation in the intrapeptide distance is less than 4, 3, 2, or 1 angstroms. It is also contemplated that larger variations in the intrapeptide distance may not prevent scaffold formation if sufficient stabilizing forces are present. This distance may be calculated based on molecular modeling or based on a simplified procedure that has been previously reported (U.S. Patent Number 5,670,483).
  • 3583475V1 37 ° f l 0 ° versus 8 atoms) is 3 angstroms.
  • substantially uniformly distributed is meant that immediately after scaffold formation at least 50, 60, 70, 80, 90, or 100% of the cells encapsulated by the scaffold are separated from each other by distances that vary by less than 500, 100, 50, 20, 10, or 1 ⁇ M.
  • iso-osmotic solute a non-ionizing compound dissolved in an aqueous solution.
  • solution that is substantially free of electrolytes is meant a solution to which no electrolytes have been added or in which the concentration of electrolytes is less than 0.01 or 0.001 mM.
  • nanoscale generally refers to structures having dimensions that may most conveniently be expressed in terms of nanometers.
  • nanoscale structure may refer to a structure having a largest dimension of approximately 500 nm or less, approximately 100 nm or less, approximately 50 nm or less, approximately 20-50 mn, approximately 10-20 nm, approximately 5-10 nm, approximately 1-5 nm, approximately 1 nm, or between 0.1 and 1 nm. "Approximately” as used herein means that the measurement may deviate by 10%) from the numeral given, and the ranges listed are assumed to include both endpoints.
  • the relevant dimension may be, e.g., length, width, depth, breadth, height, radius, diameter, circumference, or an approximation of any of the foregoing in the case of structures that do not have a regular two or three-dimensional shape such as a sphere, cylinder, cube, etc. Any other relevant dimension may also be used to determine whether a structure is a nanoscale structure, depending on the shape of the structure.
  • One of ordinary skill in the art will recognize that one or more dimensions of a nanoscale structure need not be in the nanometer range. For example, the length of such structures may run into the micron range or longer.
  • nanofiber refers to a fiber having a diameter of nanoscale dimensions. Typically a nanoscale fiber has a diameter of 500 nm or less. According to certain embodiments of the invention a nanofiber has a diameter of less than 100 nm. According to certain other embodiments of the invention a nanofiber has a diameter of less than 50 nm. According to certain other embodiments of the invention a nanofiber has a diameter of less than 20 nm.
  • a nanofiber has a diameter of between 10 and 20 nm. According to certain other embodiments of the invention a nanofiber has a diameter of between 5 and 10 nm. According to certain other embodiments of the invention a nanofiber has a diameter of less than 5 nm.
  • the term "nanoscale environment scaffold” refers to a scaffold comprising nanofibers. According to certain embodiments of the invention at least 50% of the fibers comprising the scaffold are nanofibers. According to certain embodiments of the invention at least 50% of the fibers comprising the scaffold are nanofibers. According to certain embodiments of the invention at least 75% of the fibers comprising the scaffold are nanofibers.
  • the fibers comprising the scaffold are nanofibers.
  • at least 95%> of the fibers comprising the scaffold are nanofibers.
  • at least 99% of the fibers comprising the scaffold are nanofibers.
  • the scaffold may also comprise non-fiber constituents, e.g., water, ions, growth and/or differentiation-inducing agents such as growth factors, therapeutic agents, or other compounds.
  • microscale generally refers to structures having dimensions that may most conveniently be expressed in terms of micrometers.
  • the term “microscale structure” may refer to a structure having a largest dimension of approximately 500 ⁇ m or less, approximately 100 ⁇ m or less, approximately 50 ⁇ m or less, approximately 20-50 ⁇ m, approximately 10-20 ⁇ m, approximately 5-10 ⁇ m, approximately 1-5 ⁇ m, approximately 1 ⁇ m, or between 0.1 and 1 ⁇ m.
  • the relevant dimension may be, e.g., length, width, depth, breadth, height, radius, diameter, circumference, or an approximation of any of the foregoing in the case of structures that do not have a regular two or three-dimensional shape such as a sphere, cylinder, cube, etc. Any other relevant dimension may also be used to determine whether a structure is a microscale structure, depending on the shape of the structure.
  • One of ordinary skill in the art will recognize that one or more dimensions of a microscale structure need not be in the nanometer range.
  • microfiber refers to a fiber having a diameter of microoscale dimensions. Typically a microscale fiber has a diameter of 500 ⁇ m or
  • 3583475V1 39 ° f l °° less, a diameter of less than 100 ⁇ m, a diameter of less than 50 ⁇ m, a diameter of less than 20 ⁇ m, a diameter of between 10 and 20 ⁇ m, or a diameter of between 5 and 10 ⁇ m.
  • the present invention provides a number of advantages related to the repair or replacement of tissues.
  • these methods enable the encapsulation of living cells by a peptide scaffold in a three-dimensional arrangement and in a substantially uniform distribution, which may promote the viability and proliferation of the cells.
  • the cells are present in an architecture that more closely approximates the natural situation of cells in the body than does culture in a traditional plastic culture dish or other two-dimensional substrate.
  • the peptide scaffolds comprise a network of nanofibers with intervening spaces rather than a solid matrix.
  • Such a structure may allow cell penetration and cell-cell interaction in a way that more closely resembles the setting of cells within the body than allowed by other culture techniques and materials.
  • the ability of cells to adhere to a substrate may influence cell morphology.
  • the peptide scaffolds also have the advantage of not eliciting a detectable immune or inflammatory response in mammals. Further, the peptide scaffolds exhibited no detectable swelling when scaffold added to a saline solution. This lack of swelling is probably due to the high water content of the scaffold (typically >99%>). This property of the scaffold reduces the probability of an unregulated expansion of the scaffold that could lead to adverse physiological effects on neighboring tissues. Moreover, if desired, the in vivo rate of degradation of the scaffolds maybe modulated by the incorporation of protease cleavage sites into the scaffold.
  • Sources of the cells may also include fetal or adult mammals or established cell lines. Numerous established cell lines are known in the art, many of which are available through the American Type Culture Collection (http://www.atcc.org), which also provides references describing these cell lines. In
  • a liver-derived cell is a cell that is obtained from the liver or the progeny or descendant of such a cell.
  • progeny refers not only to the immediate products of cell division but also to the products of subsequent cell divisions, i.e., to cells that are descendants of a particular cell.
  • a cell that is derived from a cell line is a member of that cell line or is the progeny or descendant of a cell that is a member of that cell line.
  • a cell derived from an organ, tissue, individual, cell line, etc. may be modified in vitro after it is obtained. Such a cell is still considered to be derived from the original source.
  • liver progenitor cells are known to exist in a wide variety of tissues (See references cited above). Cells may be obtained from any body tissue, organ, or structure.
  • cells may be derived from brain, nervous tissue, bone marrow, esophagus, fallopian tube, heart, intestines, gallbladder, kidney, liver, lung, ovaries, pancreas, prostate, bladder, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, ureter, urethra, and uterus.
  • Embryonic stem cells may be used.
  • liver stem cells or liver progenitor cells As discussed above, mature hepatocytes and other mature liver cell types are able to divide and give rise to daughter cells of the same type. However, the existence, identity, and origin of liver stem cells or liver progenitor cells and their role in liver regeneration remains unclear (See, e.g., Peterson, B. et al, "Bone
  • liver progenitor cells may be conveniently harvested from rat liver.
  • liver cells may be harvested surgically or using a less invasive liver biopsy technique.
  • Liver progenitor cells may be isolated from a mixed population of cells residing in the liver. The bone marrow is likely to be a good source of progenitor
  • 3583475vl cells having broad transdifferentiation potential (i.e., potential to differentiate into multiple different cell types).
  • the invention specifically contemplates the use of progenitor cells derived from bone marrow.
  • Cells harvested from an individual may be used either with or without a period of expansion in culture. Alternately, cells that have been propagated in culture as a stable cell line may be used. In certain embodiments of the invention the cells are autologous or allogeneic. In certain embodiments of the invention cells are harvested from a subject, e.g., a patient, and a clonal cell line is derived from one or more of these cells. Clonal lines of progenitor cells, including somatic tissue stem cells may be obtained by limiting dilution plating or single cell sorting.
  • Cells from the cell line are used in the practice of the invention. When intended for treatment of a particular patient, cells from a matched donor may be advantageously used. Cells isolated from an individual or maintained as a cell line may be cultured according to any appropriate technique including standard cell culture techniques prior to their use in the practice of the present invention.
  • telomeres may be desirable to be modified prior to their use in the invention. Numerous methods for introducing exogenous genetic material into cells are well known in the art. certain embodiments of the invention it may be desirable to introduce a selectable marker into the cells. In certain embodiments of the invention it may be desirable to introduce a gene that encodes a selectable marker (e.g., a gene encoding a protein that confers drug resistance) or a detectable marker (e.g., GFP) under the control of a tissue-specific promoter. Expression of the detectable marker may then be used as a means to determine whether the cell or its progeny has differentiated or transdifferentiated along a particular cell lineage pathway characteristic of that tissue. The marker may also be used as a means of a selectable marker (e.g., a gene encoding a protein that confers drug resistance) or a detectable marker (e.g., GFP) under the control of a tissue-specific promoter. Expression of the detectable marker may then be used as a
  • 3583475vl isolating cells that have differentiated or transdifferentiated along a particular pathway, e.g., by using immunological methods, FACS, etc., such other methods as are well known in the art.
  • Numerous selectable and detectable markers are known in the art.
  • tissue-specific, organ-specific, and lineage-specific promoters are well known.
  • Genes may be introduced under the control of either a constitutive or an inducible promoter of which many are known in the art.
  • a therapeutically desirable genetic modification may be made. For example, in a case where an individual harbors a mutation in a particular gene it may be desirable to introduce a wild-type copy of the gene into the progenitor cell for gene therapy purposes.
  • liver diseases See, e.g., Grompe, M., "Liver repopulation for the treatment of metabolic diseases", J. Inherit. Metab. Dis., 24, 231-244, 2001 for a discussion of some of these diseases.)
  • a particular receptor e.g., a growth factor receptor
  • progenitor cells it is desirable to enrich for progenitor cells.
  • Various methods of enrichment may be used. For example, the presence of particular markers may be used to remove or otherwise exclude cells that have differentiated and reached a point at which they do not qualify as progenitor cells.
  • Techniques for removing cells or sorting cells are well known in the art and include the use of flow cytometry (e.g., FACS) and various other methods employing antibodies that recognize particular cell types.
  • FACS flow cytometry
  • a clonal cell line may be established from cells to which SACK has been applied.
  • EGF epidermal growth factor
  • NGF nerve growth factor
  • PDGF platelet-derived growth factor
  • HGF hepatocyte growth factor
  • BDNF brain- derived neurotrophic factor
  • IGF-I insulin-like growth factor-I
  • TGF- ⁇ transforming growth factor ⁇
  • the growth factors may be provided in a pure form or as components of a more complex biological mixture such as serum.
  • the growth factors may be present within the culture medium of a peptide hydrogel structure in which cells are encapsulated and/or may be encapsulated within the structure itself.
  • different concentrations of a particular growth factor may exert different effects on target cells.
  • One of ordinary skill in the art will be able to test a range of concentrations and combinations in order to achieve the desired effects.
  • ECM components may be included in the peptide hydrogel. These include proteins such as fibronectin, laminin, collagens, elastin, etc., and also glycosaminoglycans, e.g., hyaluronic acid, chondroitin sulfate, and dermatan sulfate. Cells cultured within peptide hydrogels in the presence of these ECM components may also be cultured in the presence of these components after removal from the hydrogel.
  • proteins such as fibronectin, laminin, collagens, elastin, etc.
  • glycosaminoglycans e.g., hyaluronic acid, chondroitin sulfate, and dermatan sulfate.
  • 3583475vl 44 of 100 In addition to growth factors and ECM components, various other chemical stimuli or conditions may influence cell differentiation or transdifferentiation, and any of these may be used in the context of the present invention.
  • stimuli include activators of the phosphatidyl inositol pathway, or other factors that increase levels of inositol trisphosphate and/or intracellular Ca concentrations, activation of protein kinase C and/or other cellular kinases, etc.
  • the presence of small molecules including small organic molecules or metal ions may also influence cell differentiation or transdifferentiation and may be used in the practice of the invention.
  • any appropriate method may be employed to investigate and assess the effects of culturing cells in or on the peptide structures described herein.
  • the effects of the cells on the overall composition and properties of the cell/hydrogel assembly may be monitored. Such features as protein content, strength, etc., can be examined.
  • Cell viability may be assessed by examining vital dye exclusion (e.g., trypan blue exclusion).
  • Cell division may be observed by light microscopy and is indicated by the presence of mitotic figures.
  • mRNA and/or protein synthesis may also be measured by techniques well known in the art.
  • An increase in cell number accompanying division may also be observed, e.g., by counting with a hemacytometer.
  • Mo ⁇ hological changes such as cell rounding may also accompany division.
  • DNA synthesis may be monitored by detecting and/or measuring inco ⁇ oration of various substances such as radiolabeled nucleotides (e.g., 3 [H] thymidine), bromodeoxyuridine (BrdU), etc., into DNA.
  • radiolabeled nucleotides e.g., 3 [H] thymidine
  • bromodeoxyuridine (BrdU) bromodeoxyuridine
  • Cell differentiation and transdifferentiation can be assessed based on a number of parameters, including mo ⁇ hology. Cell differentiation and transdifferentiation may also be assessed by monitoring gene expression (e.g., by detecting and/or measuring mRNA by Northern blot analysis, RT-PCR, microarray analysis, etc.) or by detecting and/or measuring the presence of certain polypeptides
  • RNA and protein characteristic of particular cell types or stages, etc.
  • markers are commonly known as markers. Markers characteristic of numerous different cell types and differentiations states have been identified. In some cases such markers identify a cell as belonging to one of a restricted number of cell types but do not uniquely identify the exact cell type. In other cases the presence of a marker is believed to identify a cell as being of a particular cell type and no other, h addition to allowing identification of cell type, certain markers are characteristic of cells that lack or possess a particular feature or functional capability (e.g., cells that are post- mitotic).
  • markers that may be used to identify cells that are able to differentiate or transdifferentiating into cell types characteristic of the mature liver and markers that may be used to identify cells that have differentiated into such cells. Also of particular significance in the context of the present invention are markers that may be used to identify cells capable of differentiating or transdifferentiating along a neuronal lineage pathway, i.e., a pathway that ultimately results in the production of neurons or glia.
  • markers that may be used to identify cells capable of differentiating or transdifferentiating along a pancreatic lineage pathway, e.g., a pancreatic endocrine or exocrine cell pathway including, but not limited to, an insulin-secreting beta-cell like pathway .
  • a pancreatic lineage pathway e.g., a pancreatic endocrine or exocrine cell pathway including, but not limited to, an insulin-secreting beta-cell like pathway.
  • markers for liver precursor cells and for cells that are found in the mature liver are known in the art and are described, for example, in Grisham, J. and Thorgeirsson, S., "Liver stem cells", in Potten, C. (ed.), Stem Cells, Academic Press, San Diego, 1997.
  • a selection of markers appropriate for assessing differentiation along a liver cell pathway include the embryonic liver and oval cell marker alpha-fetoprotein (Shiojiri, N., Lemire, J.M. & Fausto, N. "Cell lineages and oval cell progenitors in rat liver development", Cancer Res. 51, 2611-2620, 1991); the hepatocyte and oval cell marker albumin (Houssaint, E. "Differentiation of the embryonic liver and oval cell marker alpha-fetoprotein (Shiojiri, N., Lemire, J.M. & Fausto, N. "Cell lineages and oval cell progenitors in rat liver development", Cancer Res. 51, 2611-2620, 1991); the hepatocyte and oval cell marker albumin (Houssaint, E. "Differentiation of the embryonic liver and oval cell marker alpha-fetoprotein (Shiojiri, N., Lemire, J.M. & Fausto
  • Cytokeratines as markers of ductal cell differentiation and islet neogenesis in the neonetal rat pancreas", Diabetes 43, 1279-1283, 1994
  • cytokeratin 7 (CK7)
  • cytokeratin 8 (CK8)
  • the presence of binucleated cells is indicative of hepatocytes.
  • markers for neuronal lineage cells are mentioned in Woodbury, D., et al, J. Neurosci. Res. 61: 364-370, 2000 and in Mahendra S. Rao (ed.) Stem cells and CNS development, Totowa, N.J. : Humana Press, 2001.
  • nestin is an intermediate filament protein expressed in neuroepithelial neuronal precursor stem cells, and its expression decreases with neuronal maturation (Lendahl, U., et al, "CNS stem cells express a new class of intermediate filament protein", Cell, 60:585-595, 1990.
  • NeuN is a neuron-specific marker expressed in postmitotic cells (Sarnat, H., et al, "Neuronal nuclear antigen (NeuN): a marker of neuronal maturation in early human feta nervous system", Brain Research, 20:88- 94, 1998).
  • Glial fibrillarary acidic protein is a classic glial astrocyte marker. These markers have been employed to demonstrate the applicability of certain embodiments of the invention (see Examples). Numerous other markers for neuronal lineage cells are known in the art.
  • markers appropriate for assessing differentiation or transdifferentiation along a pancreatic lineage pathway are the various polypeptide hormones produced by pancreatic endocrine cells, including insulin I, insulin ⁇ , glucagon, somatostatin, and pancreatic polypeptide. Additional markers associated with endocrine pancreas development include, but are not limited to, glut 2, PDX-1, Nkx2.2, Nkx ⁇ .l, PAX-4, and PAX-6 (Yang, et al., and references therein).
  • the invention provides a number of methods of treating subjects suffering from various conditions or disorders.
  • the invention provides a method of treating an individual comprising (i) identifying an individual in need of treatment; and (ii) administering a nanoscale environment scaffold or structure encapsulating cells to the individual.
  • the nanoscale environment scaffold encapsulating cells may be any of the nanoscale environment scaffolds or structures described herein, h particular, the nanoscale enviromnent scaffold encapsulating cells may comprise or consist of stem cells or progenitor cells.
  • the cells comprise liver cell lineage cells, neural lineage cells, or pancreatic lineage cells.
  • the cells comprise stem cells or progenitor cells that have been instructed or induced to differentiate.
  • the cells may be instructed or induced to differentiate along a liver cell lineage pathway, along a neural lineage pathway, and/or along a pancreatic lineage pathway.
  • the cells may comprise liver cells (e.g., liver stem cells, liver progenitor cells, hepatocytes, oval cells, bile duct cells), neural lineage cells (e.g., neurons or glia), and/or pancreatic lineage cells (e.g., endocrine cells such as ⁇ , ⁇ , ⁇ , or ⁇ cells or exocrine cells).
  • the structure encapsulating cells may contain one or more differentiation enhancing agents such as ECM components and/or growth factors.
  • Another method comprises steps of (i) culturing progenitor cells or stem cells in a peptide hydrogel thereby producing a peptide hydrogel structure containing cells; and (ii) implanting the peptide hydrogel structure containing cells into a subject.
  • the peptide hydrogel may contain one or more differentiation enhancing agents such as a growth factor or ECM component. Alternately, such an agent may
  • the method may further include a step of allowing the cells to differentiate or transdifferentiate while within the peptide hydrogel.
  • the cells differentiate along a hepatocyte lineage pathway, a neural cell lineage pathway, or a pancreatic cell lineage pathway such as an insulin secreting ⁇ -like cell pathway.
  • Cells that have differentiated along a hepatocyte lineage pathway and structures containing such cells are particularly useful for treatment of disorders and diseases of the liver including, but not limited to, physical or chemical injury, hepatitis, liver cancer, and cirrhosis.
  • Cells that have differentiated along a neural cell lineage pathway and structures containing such cells are particularly useful in treating disorders and conditions of the central or peripheral nervous system including injury, degenerative diseases, tumors, Parkinson's disease, multiple sclerosis, Alzheimer's disease, epilepsy, stroke, etc.
  • Cells that have differentiated along a pancreatic cell lineage pathway and structures containing such cells are particularly useful for treating disorders or diseases of the endocrine and/or exocrine pancreas including, but not limited to, diabetes, pancreatitis, pancreatic cancer, and cystic fibrosis.
  • Cells that are capable of secreting insulin are useful in particular for treating conditions characterized by a relative or absolute lack of insulin functional activity or characterized by insulin resistance, including, but not limited to, type I or type II diabetes.
  • At least a portion of the cells cultured in the hydrogel in the presence of particular differentiation enhancing agents produce insulin at a greater level than comparable cells cultured in the hydrogel in the absence of the differentiation enhancing agent(s).
  • at least a portion of the cells cultured in the hydrogel in the presence of particular differentiation enhancing agents produce insulin at a level at least 5%> as much insulin per milligram protein as that produced by normal islet cells.
  • at least a portion of the cells cultured in the hydrogel in the presence of particular differentiation enhancing agents produce insulin at a level at least 10% > as much insulin per milligram protein as that produced by normal islet cells.
  • 3583475vl 49 of 100 certain embodiments of the invention at least a portion of the cells cultured in the hydrogel in the presence of particular differentiation enhancing agents produce insulin at a level at least 20% as much insulin per milligram protein as that produced by normal islet cells. According to certain embodiments of the invention at least a portion of the cells cultured in the hydrogel in the presence of particular differentiation enhancing agents produce insulin at a level at least 50%, at least 75%, or as much as 100%) as much insulin per milligram protein as that produced by normal islet cells. According to certain embodiments of the invention at least a portion of the cells cultured in the hydrogel in the presence of particular differentiation enhancing agents secrete insulin in response to various stimuli including glucose, IBMX, carbachol, and/or tolbutamide.
  • cells are cultured within a peptide hydrogel structure under any of a variety of conditions, e.g., in the presence of one or more differentiation enhancing agents such as a growth factor or an ECM component and are then removed from the hydrogel.
  • Cells are then implanted into a subject in need of treatment, either immediately or after a period of culture, e.g., in a conventional culture vessel.
  • the peptide structures encapsulating cells, or cells isolated from the peptide structures after a period of culture therein may be used in the construction of artificial organs, e.g., artificial liver or pancreas
  • kits that may be used for enhancing cell differentiation and/or transdifferentiation.
  • the kits comprise a peptide hydrogel of the invention, wliich may be provided in dry or lyophyhzed form.
  • the kits may further comprise one or more of the following elements: instructions for encapsulating cells within a peptide hydrogel structure and for other uses of the system, instructions for inducing cells to differentiate or transdifferentiate within the scaffold, a vessel in wliich the encapsulation may be performed, a liquid in which the peptide can be dissolved, an electrolyte for initiating peptide self-assembly, medium for tissue culture, cells that may be encapsulated, differentiation-enhancing agents, etc. Additional elements may also be included.
  • the invention provides assay systems and methods for testing compounds. Since the liver is the major organ that metabolizes a wide range of foreign and endogenous compounds including drugs, it is great importance to determine the effects of such compounds on the liver, e.g., their ability to induce liver enzymes, and the ability of the liver to metabolize such drugs. Traditionally such assessments have initially been performed using in vitro systems such as microsomes, or in vivo animal models. However, these approaches have significant drawbacks. The microsome system does not allow for tests that include the possible effects of cell membrane barriers or other features of an intact cell. Animal models are expensive and time-consuming to employ. In addition, animal liver cells may metabolize compounds differently to human liver cells due, for example, to a different cytochrome P450 profile. The difficulties of culturing hepatocytes in vitro have precluded the development of cell-based assay systems.
  • the present invention provides an assay system for a compound comprising a peptide hydrogel structure encapsulating liver progenitor cells (non-human animal or human), wherein the liver progenitor cells have been induced to differentiate along a hepatocyte pathway and exhibit features of a mature hepatocyte such as expression of metabolic enzymes such as cytochrome P450 enzymes.
  • a compound is applied to the system, and various parameters are tested. For example, the ability of the encapsulated cells to metabolize the compound may be tested.
  • the ability of the compound to induce or inhibit P450 enzymes maybe assessed, e.g., using a fluorescent or otherwise conveniently detectable substrate such as that as described in the Examples.
  • liver parameters e.g., the synthesis of proteins such as albumin, alanine transaminase, aspartate transaminase, etc.
  • Methods for measuring a wide variety of proteins synthesized by the normal liver are well known in the art.
  • Many drugs and other foreign compounds are known to induce or inhibit liver enzymes, and such effects present significant safety concerns in terms of drug development. It is desirable to test the effects of new medication candidates upon liver enzymes.
  • the present invention provides a way of performing such tests in vitro, which may be used to predict potential dangers posed by new drug candidates, drug interactions, etc.
  • Rat somatic liver progenitor/stem cells Rat somatic liver progenitor/stem cells.
  • the isolation and preparation of the liver progenitor cells is described in detail in U.S. provisional patent application "Methods for Ex Vivo Propagation of Somatic Stem Cells", filed July 10, 2001, on which one of the present inventors (Dr. James Sherley) is a co-inventor.
  • xanthosine (Xs) was used as a pharmacological agent allowing for a switch from the default asymmetric kinetics normally exhibited by tissue stem cells to exponential kinetics.
  • Xs xanthosine
  • clonal rat liver epithelial stem cell lines that retained the ability to divide by asymmetric cell kinetics were isolated.
  • Rat liver epithelial cells found in the low-speed supernatant of centrifuged cells from in situ collagenase-perfused livers were isolated by limiting dilution cloning in the absence or presence of Xs.
  • the cell line used in this work which is termed LPC-8, LPC-8.1 (a sub-clone of LPC-8), or Xs-D8, or D8 elsewhere herein and in the above-mentioned provisional patent application, has now been maintained continuously in culture for more than 80 cell doublings. Early passage cells were cryo-preserved in liquid nitrogen and can be reestablished in culture after thawing.
  • DMEM/10%FBS/pen strep DMEM/10%FBS/pen strep and then resuspended in an aqueous solution of 10% sucrose. Cells were counted using a hemacytometer.
  • a RAD 16-1 peptide solution was prepared by dissolving peptide in deionized, distilled, sterile water at a concentration of 0.5%> w/v.
  • the RAD16-I solution was equilibrated with PBS (phosphate buffered saline) to a final concentration of IX prior to mixing with the cell suspension in order to bring the pH within a physiologic range.
  • Cells were mixed with RAD 16-1 solution at a final concentration of approximately 100,000 cells/ml.
  • the cell/peptide mixture was loaded into multiwell (96-well) plates at 50 ⁇ l/well. Immediately after loading, 200 ⁇ l of culture medium (DMEM/10%FBS/pen/strep) was added to each well, thereby providing an electrolyte concentration sufficient to allow self-assembly of the gel into a three- dimensional structure. After gel self-assembly, the media was changed three to four times to allow proper equilibration of the cell/hydro gel assembly. The final cell density was between 1-2 x 10 5 cells/ml of hydrogel. The multiwell plates were cultured at 37° C in a standard incubator containing a humidified chamber equilibrated with 5%> CO 2 . Cell viability was measured by staining with trypan blue according to standard techniques. Viability 24 hours after encapsulation was typically greater than 85%>.
  • Control Cells Control cultures of LPC-8.1 cells were initiated at the same time as the encapsulation using a portion of the cell/sucrose suspension. Cells were maintained on plastic culture dishes in DMEM/10%FBS/pen/strep at 37° C in a standard incubator containing a humidified chamber equilibrated with 5% CO 2 . Cell
  • 3583475vl 53 of 100 viability was measured by staining with trypan blue according to standard techniques. Viability 24 hours after plating was typically greater than 90%.
  • LPC-8 cells were also grown on the surface of plates coated with assembled RAD 16-1 hydrogel in DMEM/10%FBS/ ⁇ en/strep and maintained at 37°C in 5% CO 2 .
  • LPC-8 cultures in soft agar were also prepared according to standard protocols.
  • BrdU Staining Cell division within the assembled peptide hydrogel was assessed by monitoring inco ⁇ oration of 5'-bromodeoxyuridine (BrdU). BrdU was added to the culture medium at a final concentration of 10 ⁇ M for a period of 18 hours.
  • hydrogel cultures were incubated in BrdU-free medium for two hours. Hydrogels were then washed in PBS, followed by fixation in 2% paraformaldehyde in PBS (pH 7.4) at room temperature for 2 hours. Following fixation, hydrogels were washed several times in PBS and then treated with 0.1% Triton X-100 in PBS for 2 hours at room temperature. To achieve DNA denaturation, hydrogels were then treated with 2N HC1 in PBS for 30 minutes at 37° C . Following this treatment, several washes with PBS were performed until a pH of 7.4 in the wash solution was reached. Hydrogels were then incubated in blocking buffer (20% FBS, 0.1% Triton X-100, 1% DMSO in PBS) for four hours at room temperature with slow shaking.
  • blocking buffer (20% FBS, 0.1% Triton X-100, 1% DMSO in PBS
  • FITC-conjugated, anti-BrdU mouse monoclonal antibody IgG] (BD Phanningen, catalog number 33284X) was preincubated in blocking buffer for one hour at room temperature at a dilution of 1 :400 and then added to samples overnight at 4° C with slow shaking. Following incubation, hydrogels were washed three times with blocking buffer for two hours, following which a final one hour wash with PBS was performed.
  • Control cells and hydrogels were observed under a Nikon microscope TE300 with phase contrast and fluorescence using an Openlab acquisition system mounted with a Hamamatsu video camera. Pictures obtained represent a single optical plane observed with phase contrast and fluorescence.
  • FIG. 3a shows encapsulated LPCs immediately after encapsulation, illustrating uniform, single-cell dispersion. When cells divide symmetrically in three dimensions, they tend to form compact, spheroidal clusters. However, if cell division is asymmetric, since only one cell of the initial cluster divides, a linear or sometimes branched cluster is formed.
  • Figure 3b shows encapsulated LPCs two days after encapsulation.
  • Cell Culture Cells were cultured in standard plastic culture dishes and encapsulated in peptide hydrogels as described in Example 1. Controls and encapsulated cells were initially maintained in identical media (DMEM/10%FBS/pen/strep) and under identical culture conditions.
  • HGM Base medium: DMEM from Gibco, #11054-020 (500ml), 0.015 g L-Proline, Sigma # P-4655, 0.05 g L-Ornithine, Sigma # O-6503, 0.305 g Niacinimide, Sigma # N-0636, 0.5 g D-(+)-Glucose, Sigma # G-7021, 1 g D-(+ galactose, Sigma # G-5388, 1 g Bovine Serum Albumin, fraction V, Sigma # A- 9647; 500 ml of trace metal solutions: ZnC12: 0.0272 g, ZnSO4-7 H2O: 0.0375 g, CuSO4-5 H2O: 0.01 g, MnSO4: 0.00125 g; 12.5 ml L-Glutamine, final concentration [5 mM], Gib
  • EROD 7-ethoxyresofurin O- deethylase activity
  • Cytochrome P450 1A1 enzyme activity, characteristic of fully differentiated hepatocytes, was analyzed over time both visually and using a quantitative assay in cells grown on plastic culture plates and in cells encapsulated within the peptide hydrogel structure.
  • CYPIAI Cytochrome P450 1A1
  • Figure 4a LPCs growing as a monolayer on a standard plastic culture dish did not display detectable EROD activity two weeks after plating.
  • LPCs in spheroids growing over the same time period in an assembled peptide structure exhibited abundant EROD activity at two weeks as evidenced by the red staining seen within cells. All spheroids examined contained EROD positive cells. The percentage of positive cells within a cluster ranged between approximately 50 and 80 percent.
  • FIG. 4c is a graph showing EROD activity of LPC spheroids growing in an
  • Switching control cells growing on standard tissue culture plates to hepatocyte growth medium had no effect on EROD activity, which remained at essentially undetectable levels after one week of culture in HGM.
  • switching encapsulated cells to HGM resulted in a 3 to 4 fold increase in EROD activity after one week of culture relative to the level of EROD activity in encapsulated cells maintained in DMEM/10%FBS/pen/strep.
  • Switching encapsulated cells to HGM also resulted in a dramatic change in cellular mo ⁇ hology in a fraction of the cells, as described in Example 3.
  • EROD activity was also examined in LPC-8.1 cells grown on standard tissue culture dishes under serum starvation conditions (DMEM with 1%FBS) and in LPC-8.1 cells induced to form floating spheroids. EROD activity in serum-starved cells and cells that formed floating spheroids remained at extremely low levels when measured one week after plating.
  • Figure 4d is a graph summarizing the data on comparative CYPIAI activity of LPC-8.1 cells maintained under these various culture conditions: monolayer on plastic dish with low (1%) serum concentration (serum starvation); spheroid culture obtained by growing LPCs in liquid culture at high density; spheroid culture in assembled peptide structure growing in DMEM with 10% FBS; spheroid culture in assembled peptide structure growing in HGM.
  • the LPC-peptide hydrogel system is the first described in vitro model for transdifferentiation by a clonal stem cell that retain differentiation properties after long-term growth in culture.
  • LPC-8.1 cells were grown either in DMEM/10% FBS/pen/strep as above or in hepatocyte growth medium.
  • human Epidermal Growth Factor (EGF) at final concentration of 20ng/mL R&D
  • rat Beta Neural Growth Factor ( ⁇ -NGF) at final concentration of 5 ng/mL (R&D, Systems, catalog number: 556-NG-100), and human Platelet Derived Growth Factor (PDGF) at final concentration of lOng/mL (R&D, System, catalog number: 120-HD-001) was added to the medium (either DMEM or HGM).
  • ⁇ -NGF rat Beta Neural Growth Factor
  • PDGF Platelet Derived Growth Factor
  • P19 and NIH3T3 cells were cultured according to standard protocols as previously described by the American Type Culture Collection (ATCC) (see http://www.atcc.org). Retinoic acid treatment of P19 cells to induce neuron/glia differentiation was performed as previously described (Bain, G., et al, "Neuronlike Cells Derived in Culture from P19 Carcinoma Embryonal Stem Cells", in Culturing Nerve Cells, 2nd edition, Banker, G. and Goslin, K, (eds.), 1998).
  • ATCC American Type Culture Collection
  • the primary antibody in each case was preincubated in blocking buffer for one hour at room temperature (normally at final concentration of 1 ⁇ g/ml) and then added to the samples and incubated overnight at 4 C with slow shaking.
  • the primary antibodies used were: Goat polyclonal IgG anti-GFAP (Santa Cruz Biotechnology, CA, catalog number: sc-
  • the secondary antibodies used were: Goat anti-mouse IgG Rhodamine-conjugated (Santa Cruz Biotechnology); Goat anti-mouse IgG FITC- conjugated (Santa Cruz Biotechnology), and donkey anti-goat -FITC-conjugated (Santa Cruz Biotechnology) .
  • the samples were then washed three times with blocking buffer for 2 hours. One final wash with PBS for another hour concluded the treatment.
  • the hydrogels were then monitored under a Nikon microscope TE 300 with phase contrast and fluorescence using an Openlab data acquisition system mounted with a Hamamatsu video camera. Three independent clusters including a total of approximately 100 cells were observed for each staining. Pictures obtained represent one single optical plane observed with phase contrast and fluorescence for FITC and Rhodamine.
  • BrdU Staining was performed as in Example 2.
  • FIGS. 5b and 5d show that encapsulated LPC 8.1 cells stained positively for the neuronal progenitor markers Nestin and ⁇ - tubulinlll respectively. Most of the cells exhibiting a neuronal mo ⁇ hology stained positive for Nestin and ⁇ -tubulinfll. However, encapsulated LPC 8.1 cells stained very poorly for NeuN, a marker for differentiated, post-mitotic neurons (Figure 5f). Encapsulated LPC 8.1 cells were negative for GFAP, a marker for mature,
  • 35834 conducted75v ,l 60 of 100 differentiated glial cells (astrocytes).
  • glial cells astrocytes.
  • the mo ⁇ hological analysis and marker staining results suggested that encapsulation within the peptide hydrogel structure provided an environment that allowed the cells to alter their differentiation potential in response to extracellular factors present within HGM.
  • HGM contains 20 ng/ml of epidermal growth factor (EGF)
  • EGF epidermal growth factor
  • NGF or PDGF was able to support cell viability or induce mo ⁇ hological changes when encapsulated cells were cultured in HGM lacking EGF or in DMEM lacking serum.
  • NGF alone was added to encapsulated hydrogel cultures growing in DMEM with 10% FBS, a similar dramatic change in cell mo ⁇ hology as occurred in HGM medium was observed, i.e., within 24 hours approximately 10-20% of the cells exhibited a neuronal-like appearance with elongated cell bodies with rudimentary processes.
  • NGF was present in either DMEM/10% FBS, DMEM/EGF, or HGM/EGF it clearly promoted
  • BrdU positive cells tended to be randomly located within the clusters and exhibited a more spherical mo ⁇ hology. h some cases BrdU staining was observed in cells showing a neuronal mo ⁇ hology. The presence of NGF resulted in an enhancement of the number of cells exhibiting a neuronal phenotype.
  • Peptide hydrogel cultures permit differentiation of somatic liver progenitor cells.
  • LPC- 8 cells that had been growing for one week within a peptide hydrogel structure in HGM containing EFG and NGF were extracted from the hydrogels with mechanical disruption and plated onto laminin-coated plates with the same media and growth factor combinations used with the hydrogel.
  • Cells on the plates acquired two basic mo ⁇ hologies over the course of a week: (1) classical hepatocyte shape with expanded cell bodies and mono- or bi-nuclear appearance (Figure 7a); (2) flat, expanded, with some processes (Figure 7b). At one week after plating, all cells on the plate stained negative for both Nestin and ⁇ -tubulinUI.
  • Cells of class 1 (hepatocyte-like mo ⁇ hology) stained negative for both NeuN and GFAP but did exhibit CYPIAI activity.
  • cells of class 2 (glia-like) stained positive for GFAP ( Figure 7d, 7f) and negative for NeuN and did not exhibit CYPIAI activity.
  • LPC 8.1 cells were cultured in DMEM containing 10%> fetal bovine serum (FBS) and Xs (400 ⁇ M) and monitored for a period of 4 days. Control cells were grown on conventional polystyrene tissue culture dishes. Cells were encapsulated in RAD 16-1 hydrogel (0.5% w/v) as described above. For some experiments cells were removed from the hydrogels by mechanical disruption and transferred to conventional tissue culture dishes, where they were maintained in the same medium. Since no enzymatic digestion is used, spheroids can be successfully transferred to conventional tissue culture dishes almost entirely intact to facilitate analysis. Cells were counted using a hemacytometer.
  • FBS fetal bovine serum
  • Xs 400 ⁇ M
  • the media used was DMEM with 10% fetal bovine serum and xanthosine (400 ⁇ M) to induce exponential growth of LPC-8 cells. Cells were cultured for 24 hr, and the number of cells per colony was counted by visual inspection under a stereo microscope. Data is expressed as mean value ⁇ standard deviation (SD).
  • LPC-8.1 cells were grown in DMEM/10% FBS/pen strep as described above. Cells were encapsulated in RAD 16-1 hydrogels as described above. Cell and Spheroid Extraction from the Hydrogels. LPC-8.1 cells were cultured for 48 hrs on regular (i.e., conventional) cell culture dishes at a density of -10,000 cells/cm 2 (controls) or for 96 hrs after encapsulation in RAD16-I hydrogels (0.5% w/v) at a
  • Immunostaining was performed as described above except that 4%> paraformaldehyde was used.
  • Primary antibodies used were: rabbit polyclonal anti- rat Cytochrome P450 enzyme CYPIAI and CYP1 A2 (CHEMICON International, catalog number: AB1255), rabbit IgG anti-rat albumin-HRP (Accurate Chemicals, YNGRAALBP), rabbit IgG anti-rat C/EBP ⁇ (Santa Cruz Biotechnology, catalog number: sc-61), mouse IgGl monoclonal anti-rat Cytokeratin 8 (CHEMICON International, h c. MAB 1673), (CHEMICON International, hic.
  • MAB3226 mouse IgGl monoclonal anti-Cytokeratin 18 (Santa Cruz Biotechnology, sc-6259), mouse IgGl monoclonal anti-Cytokeratin 19 (Santa Cruz Biotechnology, sc-6278). Secondary antibodies used were: goat anti-mouse IgG Rhodamine-conjugated (Santa Cruz Biotechnology, catalog number: sc-2029); donkey anti-rabbit Rhodamine- conjugated (Santa Cruz Biotechnology, catalog number: sc-2095).
  • Measurement of CYPIAI Activity Measurement of CYPIAI activity was performed essentially as described above.
  • LPC-8 cells were cultured in DMEM/FBS either on conventional tissue culture dishes (control) or in RAD 16-1 peptide hydrogels for either 48 hours (control) or 96 hours (encapsulated). At this time the cell numbers were approximately equivalent. Cells were then removed from their respective culture environment either by trypsinization (for control cultures) or by mechanical disruption (for spheroids isolated from hydrogels). Cells were then cultured in the same medium overnight on conventional tissue culture dishes to allow spheroid colonies to form. Spheroids were then immunostained for expression of various markers.
  • Figure 9 shows phenotypic analysis of LPC cells during exponential growth on conventional culture dish either after isolation from regular culture conditions or after isolation from peptide hydrogel culture.
  • Figures 9a, 9c, 9e, 9g, 9i, and 9k show phase contrast micrographs of control or spheroid-derived colonies.
  • Figures 9b, 9d, 9f, 9h, 9j, and 91 show the same colonies immunostained to show expression of C/EPB ⁇ , albumin, or CYP1A1/1A2.
  • Table 4 presents a semi-quantitative comparison of expression of these and the additional markers ⁇ -fetoprotein, cytokeratin 18 (CK18), and cytokeratin 19 (CK19) in control and spheroid-derived colonies.
  • Table 4 also compares the CYPIAI activity and the number of binucleated cells (consistent with a hepatocyte phenotype) in control and spheroid- derived colonies.
  • the expression of ⁇ -fetoprotein did not change after culturing LPC-8 cells in hydrogels, suggesting that the treatment did not affect the expression of the fetal marker (Table 4).
  • the developmental marker C EBP ⁇ was highly expressed in most of the nucleus of 2 and 10 days-old spheroid-derived colonies compared to the expression in control colonies. This provides evidence that LPC-8 cells encapsulated in hydrogels initiate differentiation along a pathway consistent with hepatic lineage cells (Fig. 9a-9d and Table 4).
  • Other hepatic markers such as
  • CYPl A2 was also up-regulated dramatically in hydrogel-derived spheroid colonies indicating the presence of a potential hepatic function in the hydrogel cultures (Fig. 9i-91, Table 4).
  • Low CYPIAI activity (0.02+0.01 pmol/cell/hr) was detected in exponentially growing cells on conventional culture dishes (Table 4).
  • an increase in CYPIAI activity (0.09+0.01 pmol/cell/hr) was observed. This activity was
  • LPC-8 is a clonal, somatic (liver-derived) stem cell that can be instructed to differentiate into a hepatocyte lineage by culturing in a nanoscale environment comprising nanoscale fibers.
  • LPC-8 cells can be instructed to differentiate into a hepatocyte lineage by culturing them in a three-dimensional nanofiber environment comprising a self-assembling peptide hydrogel.
  • LPC-8 cells may also be instructed to differentiate into neural lineages by culturing them in a nanoscale environment comprising nanoscale fibers, e.g., by culturing them in a three-dimensional nanofiber environment comprising a self-assembling peptide hydrogel.
  • ⁇ -fetoprotein present in fetal hepatocytes and hepatic oval cells
  • C/EBP ⁇ marker for hepatocytes, intestinal epithelial cells, and fat cells
  • albumin marker for hepatocytes and hepatic oval cell
  • CK18 expressed in hepatocytes, biliary duct epithelium and hepatic oval cells
  • CK19 expressed in biliary duct epithelium and hepatic oval cell
  • CYPl A1/CYP1A2 present in hepatocytes and other cells
  • Binucleated cells common phenotype in hepatocytes.
  • LPC-8.1 cells were grown in DMEM/10% FBS/pen/strep as described above. Cells were encapsulated in RAD 16-1 hydrogels as described above. LPC-8.1 cells were cultured on regular (i.e., conventional) cell culture dishes at a density of -10,000 cells/cm 2 (controls) or after encapsulation in RAD16-I hydrogels (0.5% w/v) at a density of -100,000 cell/ml.
  • Cytochrome P450 induction by 3-methylcholanthrene (3-MC) was added to the culture media of control and hydrogel cultures at a final concentration of 2 ⁇ M starting on the fourth (4 ) day of culture. The media containing 3-MC was replaced (50%) every other day.
  • Cytochrome P450 1A1 and 1A2 activities were analyzed over time in LPC-8 cells growing on regular culture plates and in hydrogel derived LPC spheroid colonies isolated and cultured as described above using an in situ assay (Donato, M.T., Gomez-Lechon, M.J.
  • the incubations were carried out for 15 min at 37°C in the presence of 3 ⁇ M of 7-ethoxyresorufin or 3 ⁇ M of 7-methoxyresorufin and 10 ⁇ M of dicumarol (Sigma) that prevents the decay of resorufin due to further metabolism by cytosolic oxidoreductases.
  • the resorufin product was measured by the increase in the fluorescence intensity using excitation/emission filters of 530/590 nm, respectively.
  • Resorufin product concentration was calculated based on a known resorufin standard curve obtained using the same culture media.
  • the CYP activity was expressed in units of pmol resorufin produced/cell/hour.
  • TLC thin layer chromatography
  • the samples were centrifuged at 14,000 ipm and an aliquot of 5 ⁇ L (5%>) were loaded on a thin layer chromatography (TLC) plate (silica gel 60, F254 ENSCIENCE) with external standards (Sigma) of caffeine (1,3,7-trimethylxanthine), theophylline (1,3- dimethylxanthine), theobromide (3,7-dimethylxanthine), paraxanthine (1,7- dimethylxanthine), 3-methylxanthine, xanthine.
  • the plate was developed using the organic solvent mix chloroform acetone (1 : 1) as a mobile phase.
  • FIG. 10 presents the time course of CYPIAI and CYP1A2 activity in control cultures (Fig. 10a and 10b) and hydrogel derived cultures (Fig. 10c and lOd) either in the presence (squares) or absence (circles) of treatment with the polycyclic aromatic hydrocarbon 3-MC starting at a time indicated by the arrow.
  • Untreated control cultures exhibited only weak CYPIAI activity, and activity of CYP1A2 activity was undetectable (Fig. 10a and 10b).
  • CYPIAI activity in untreated spheroid colonies exceeded that in the control by 3 to 4-fold, and activity continued to increase during the ten-day experimental period (Fig. 3d).
  • CYP1A2 activity also increased to a detectable level in untreated spheroid colonies remained stable for the longest period of evaluation, 10 days (Fig. lOd).
  • 3583475vl (AHR) control and hydrogel derived cultures were incubated in the presence of 3- methylcholanthrene (3-MC), which is known to induce CPY1 Al and CYP1A2 expression through the ligand-activated transcription factor AHR (Burbach, et al.).
  • 3-MC 3- methylcholanthrene
  • both CYP activities were induced by 3-MC treatment in the hydrogel derived spheroid colonies (Fig. 10c and lOd) but not in control cultures (Fig. 10a and 10b).
  • CYPIAI and CYP1A2 activities were increased by about 100%> and 300%, respectively, relative to the activity in non-induced samples.
  • Caffeine (1,3,7-trimethylxanthine) was used to analyze the CYP1A2 activity of the hydrogel cultures because it has previously been described that CYP 1 A2 specifically catalyzes the 3-N-demethylation of caffeine to produce paraxanthine (1,7-dimethylxanthine)
  • CYP 1 A2 specifically catalyzes the 3-N-demethylation of caffeine to produce paraxanthine (1,7-dimethylxanthine)
  • P-450IA2 Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and ⁇ -oxidation of carcinogenic arylamines.
  • hydrogel cultures exposed to 3- MC displayed approximately a three to four fold greater amount of the product paraxanthine relative to uninduced cultures (Table 5), suggesting again that the increment in CYPl A2 activity observed might be due to the ligand-activated transcription factor AHR.
  • Caffeine (caffeine-8-[ 14 C], 0.4 mM) was incubated in vivo in control and hydrogel cultures exposure or not to 3-methylcholanthrene (3-MC).
  • Amount of paraxanthine obtained is expressed in pmol/day/10 4 cells.
  • LPC-8 cells were encapsulated in RAD 16-1 hydrogel (-100,000 cells/well) in multi-well inserts (0.5 mm diameter) so that media could diffuse through evenly from the bottom essentially as described in Example 1 except that for experiments involving fibronectin or laminin, either fibronectin (100 ⁇ g/ml) or laminin (100 ⁇ g/ml) was added to the cell suspension prior to mixing with the hydrogel solution.
  • each insert contained 50 ⁇ L of cell suspension in 10% sucrose (w/v) in the absence or presence of fibronectin (50 ⁇ g/ml ) or laminin (50 ⁇ g/ml); this suspension was mixed with 50 ⁇ L of hydrogel solution (0.5%> final concentration of peptide) by pipetting up and down several times.
  • Regular culture media (DMEM, high- glucose, 25 mM, without sodium pyruvate/10% FCS/pen- strep) containing EGF (0.8 ng/ml), FGF-2 (0.5 ng/ml), or a mix of both (0.8 ng/ml EGF and 0.5 ng/ml FGF-2) was added to the well bottom (0.5 ml) in order to contact the insert membrane and initiate hydrogel formation.
  • FGF-2 is also referred to as basic FGF, FGF ⁇ , or ⁇ FGF). Unless otherwise stated all medium used in the experiments in this Example included 10%o FCS/pen/strep.
  • Immunofluorescent analysis Immunostaining was used to detect the presence of insulin in cells. After encapsulation in hydrogels, incubation, subsequent disruption of hydrogel cultures, and overnight plating in DMEM to allow colony formation, cells were fixed with 2%> paraformaldehyde in PBS for 2 hours, washed with PBS, treated with 0.1 % Triton X- 100 in PBS for 2 hours, and incubated in blocking buffer (20% calf serum, 0.1% Triton X-100; 1% DMSO in PBS) for 4 hours at room temperature. The cells were then treated with anti-insulin mouse monoclonal antibody (Sigma) overnight, followed by anti-mouse IgG FITC-conjugated for detection under a Nikon microscope TE300.
  • Induction of insulin release by glucose and other agents To detect and quantify insulin release in response to glucose induction, cells were cultured in hydrogels under optimum differentiation conditions (two weeks in hydrogel containing laminin; DMEM with high glucose, EGF + FGF with switch to low glucose DMEM with nicotinamide for the final two days followed by spheroid extraction and plating overnight on laminin-coated dishes).
  • the plated cells were cultured in DMEM (5 mM glucose) and then incubated at 37°C with different concentrations of glucose (from 0 to 40 mM) for 10 min in Krebs-Ringer buffer (NaCl, 120 mM; KC1, 5 mM; CaCl 2 ; 2.5 mM; MgCl 2 , 1.1 mM; NaHCO 3 , 25 mM; BSA, 0.1%) at 37°C.
  • Krebs-Ringer buffer NaCl, 120 mM; KC1, 5 mM; CaCl 2 ; 2.5 mM; MgCl 2 , 1.1 mM; NaHCO 3 , 25 mM; BSA, 0.1%) at 37°C.
  • 3583475vl insulin detection (Alpco) was used to analyze the supernatant for insulin release and the cell extract for cellular insulin content.
  • the assay was performed according to the directions of the manufacturer.
  • Total protein levels were determined using a protein detection kit (Bio Rad) to normalize insulin amounts according to total protein levels in each well. Assays were performed in triplicate and standard deviation was calculated. Analysis of intracellular insulin content may be performed using a protocol involving extraction with acetic acid/ethanol solution (10%> acetic acid in ethanol) as described Lumelsky, et al., 2001.
  • LPC-8 cells were also cultured on laminin- and fibronectin-coated plates (Becton & Dickinson) in media containing EGF and FGF-2 at the same concentrations as used for hydrogel cultures. They were subsequently stained for insulin expression. Results ' Cells cultured in hydrogels with ECM components form distinctive islet-like structures. The appearance of cells cultured in hydrogels in DMEM high glucose with different combinations of EGF and/or FGF and in the presence or absence of fibronectin or laminin was monitored daily.
  • Clusters were generally evident in the cultures containing fibronectin and laminin within one week of encapsulation, and such clusters were consistently observed within two weeks.
  • the clusters differed in both size and structure from clusters observed under conditions favoring differentiation into hepatocyte-like cells (e.g., DMEM/10% FBS/pen/strep as described in Examples above).
  • fibronectin or laminin the clusters were much larger, contained many more cells, and exhibited a more well defined structure than in the absence of these ECM components.
  • the ECM+ clusters contained a flat layer of cells on the surface that cover a group of approximately 50-100 cells in the interior.
  • Figure 11 compares control clusters grown in peptide hydrogels in the absence of growth factors and ECM components (Fig. 1 la, 1 lb) and clusters grown in peptide hydrogels in the presence of laminin, EGF, and FGF-2 (Fig. 1 lc, 1 Id). Clusters were grown for 8 days in both cases. The larger size and more organized structure of the clusters in Fig. l ie and 1 Id is readily apparent. Arrows indicate the surface cells.
  • 3583475vl Insulin production by cells in hydrogel culture After one to two weeks in hydrogel culture the medium was switched to low glucose medium with nicotinamide but without growth factors, and cells were cultured for an additional two days. Clusters were isolated from the hydrogels and plated on laminin-coated regular tissue culture dishes overnight to allow colony reformation. Immunostaining the colonies with an anti-insulin antibody demonstrated that colonies grown in the presence of laminin with EGF, FGF-2 or both or in the presence of fibronectin with EGF, expressed high numbers of insulin granules. Colonies grown in hydrogels in the absence of laminin, fibronectin, and/or EGF did not show insulin staining.
  • Table 7 summarizes results obtained using an 8 day differentiation protocol and also indicates relative number of colonies that stained positive for insulin.
  • Figure 12 shows insulin staining of a control colony grown in the absence of ECM components and growth factors (Fig. 12b), a colony grown in the presence of fibronectin and EGF (Fig. 12d), and a colony grown in the presence of laminin and EGF + FGF-2 (Fig. 12f). Brightly staining insulin granules are readily visible in Figures 12d and 12f but are absent in Figure 12b.
  • Spheroid-colonies prepared from different hydrogel culture conditions presented in the Table were immunostained using a mouse monoclonal antibody anti-rat insulin.
  • the amount of granules in each case is expressed as: -, no detected presence of insulin granule-containing cells in spheroid-colonies; +, presence of insulin granules in approximately 25 %> of cells per spheroid-colony; ++, presence of insulin granules in approximately 50% of cells per spheroid-colony.
  • Glucose induces insulin release by hydrogel derived pancreatic ⁇ -cell-l ⁇ ke colonies. After one to two weeks in hydrogel culture the medium was switched to low glucose medium with nicotinamide but without growth factors, and cells were cultured for an additional two days. Clusters were isolated from the hydrogels and plated on laminin-coated regular tissue culture dishes overnight to allow colony reformation. Cells were then exposed to a variety of different compounds known to stimulate insulin secretion.
  • glucose (0 to 40 mM); carbachol, an agonist of muscarinic cholinergic receptors; 3-isobutil-l-methylxanthine (IBMX), an inhibitor of cyclic- AMP phosphodiesterase; and tolbutamide, a sulfonylurea inhibitor of ATP-dependent K+ channel.
  • carbachol an agonist of muscarinic cholinergic receptors
  • IBMX 3-isobutil-l-methylxanthine
  • tolbutamide a sulfonylurea inhibitor of ATP-dependent K+ channel.
  • the latter three compounds were used in conjunction with low glucose (5 mM). Supernatant was analyzed to measure insulin release.
  • Figure 13 compares insulin release by cells exposed to various stimulants. Assays were performed in triplicate and error bars represent standard deviation. As indicated in Figure 13, cells cultured in higher concentrations of glucose released higher levels of insulin, with a background release of approximately 8-11 ng of insulin/mg protein at 0 and 5 mM glucose, respectively, and a higher release of approximately 37 ng of insulin/mg protein at 10 mM glucose concentration. Spheroid clusters grown in hydrogels without either laminin, fibronectin, or growth factors released a small amount of insulin (approximately 3-4 ng/mg protein) at low glucose concentrations (0 or 5 mM) and do not respond to increased glucose with an increase in insulin release. Thus these cells do not demonstrate the glucose-
  • 3583475vl stimulated insulin release characteristic of islet cells.
  • the dramatic response to the change in glucose concentration reflects a physiological behavior of the hydrogel derived pancreatic ⁇ -cell-like cells.
  • hepatic oval cells are not a good source of cells for tissue engineering because they must generally be obtained by hepatic chemical injury with 2-acetylamino-fluorene. This procedure is not satisfactory for modem bio engineering, which requires stem cells to be isolated for human patients without harmful procedures.
  • Insulin secretion in the system described herein occurs in response to physiologically relevant changes in glucose concentrations, in the same way as normal cells from the pancreatic islets respond in vivo. Secretion levels may be increased by modulating culture conditions (e.g., by systematically altering ECM components and concentrations, growth factor concentrations and combinations, glucose concentration of medium, etc.). The functional activity of the insulin can readily be tested using assays known in the art. In addition, in vivo rescue of insulin-deficient animal models such as the diabetic NOD-scid mouse following implantation of insulin-secreting cells can be demonstrated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions présentant des cellules, par exemple, des cellules souches, des cellules embryonnaires et leur progéniture encapsulées dans des structures d'hydrogel peptidique tridimensionnelles à autoassemblage (échafaudages). Lesdits échafaudages constituent des environnements nanométriques. L'invention concerne donc un échafaudage d'environnement nanométrique encapsulant des cellules. Selon certains modes de réalisation de l'invention, les cellules souches et/ou leur progéniture peuvent se différentier ou se transdifférentier dans les structures. Selon certains modes de réalisation de l'invention, les cellules sont présentes ou se différencient dans des cellules de lignée hépatique, dans des cellules de lignée neuronale ou dans des cellules de lignée pancréatique. L'environnement d'hydrogel peptidique rend les cellules tolérantes à l'instruction par des agents activant la différentiation tels que des facteurs de croissance ou des composants de matrice extracellulaire. L'invention concerne un système de culture in vitro permettant de mettre en culture des cellules embryonnaires et souches, en vue d'induire leur différentiation et leur transdifférentiation et en vue d'étudier leurs propriétés; un système de culture in vitro permettant de mettre en culture des cellules de type hépatocytes et/ou hépatocytes mûrs, lequel peut être utilisé, par exemple, pour propager des virus hépatotropes; un système permettant de générer des cellules sécrétant de l'insuline; un système permettant de commander et de manipuler la différentiation et la transdifférentiation cellulaire in vitro, système à partir duquel des cellules peuvent être extraites puis conservées in vitro ou administrées à un sujet; un système permettant de commander et de manipuler la différentiation et la transdifférentiation cellulaire in vitro ainsi que des systèmes d'analyse permettant de tester des composés. L'invention concerne des méthodes de traitement de maladies par implantation de structures d'hydrogel peptidique contenant des cellules ou des cellules extraites après culture dans des hydrogels peptidiques dans le corps.
PCT/US2003/021981 2002-07-15 2003-07-15 Reprogrammation cellulaire dans un hydrogel peptidique et utilisations associees WO2004007683A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003274900A AU2003274900A1 (en) 2002-07-15 2003-07-15 Cellular reprogramming in peptide hydrogel and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19394202A 2002-07-15 2002-07-15
US10/193,942 2002-07-15

Publications (2)

Publication Number Publication Date
WO2004007683A2 true WO2004007683A2 (fr) 2004-01-22
WO2004007683A3 WO2004007683A3 (fr) 2005-09-09

Family

ID=30114638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/021981 WO2004007683A2 (fr) 2002-07-15 2003-07-15 Reprogrammation cellulaire dans un hydrogel peptidique et utilisations associees

Country Status (2)

Country Link
AU (1) AU2003274900A1 (fr)
WO (1) WO2004007683A2 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038737A1 (fr) 2004-10-07 2006-04-13 Toyota Jidosha Kabushiki Kaisha Dispositif et procédé pour commander un moteur à combustion interne
WO2007000979A1 (fr) * 2005-06-27 2007-01-04 Menicon Co., Ltd. Peptide auto-assemble et gel fabrique a partir de ce peptide
JP2007217375A (ja) * 2006-02-17 2007-08-30 Nagoya Institute Of Technology 自己組織化ペプチド
JP2007217376A (ja) * 2006-02-17 2007-08-30 Nagoya Institute Of Technology 自己組織化ペプチド組成物
EP1833504A2 (fr) * 2005-01-04 2007-09-19 The Brigham And Women's Hospital, Inc. Liberation prolongee de pdgf au moyen de nanofibres de peptides autoassembles
US7332336B2 (en) 2003-08-19 2008-02-19 Effector Cell Institute, Inc. Methods for inducing differentiation of pluripotent cells
US20110020452A1 (en) * 2006-08-22 2011-01-27 The Trustees Of Columbia University In The City Of New York Progenitor cell replication and differentiation in 3d
WO2011072483A1 (fr) * 2009-12-14 2011-06-23 The University Of Hong Kong Compositions et méthodes permettant de contrôler la prolifération et la différenciation des cellules
US8080418B2 (en) 2007-03-09 2011-12-20 Corning Incorporated Method of making a three dimensional cell culture matrix
WO2012056111A2 (fr) 2010-10-27 2012-05-03 Upm-Kymmene Corporation Compositions d'administration de médicaments
JP5263756B2 (ja) * 2005-09-30 2013-08-14 国立大学法人 岡山大学 細胞の培養方法および細胞培養物
US8546338B2 (en) 2010-12-08 2013-10-01 Johnson & Johnson Consumer Companies, Inc. Self-assembling hydrogels based on dicephalic peptide amphiphiles
WO2014049204A1 (fr) 2012-09-25 2014-04-03 Upm-Kymmene Corporation Culture de cellules tridimensionnelles
WO2016097490A1 (fr) 2014-12-18 2016-06-23 Upm-Kymmene Corporation Test de substance chimique
DE102015000363A1 (de) 2015-01-20 2016-07-21 Emc Microcollections Gmbh Neue modular funktionalisierbare Peptid-Hydrogele
EP3418377A1 (fr) 2017-06-22 2018-12-26 UPM-Kymmene Corporation Échafaudage de cellulose nanofibrillaire de support conçu pour développer des cellules
CN109810943A (zh) * 2019-03-21 2019-05-28 河南科技大学 一种猪肌源性间充质干细胞分离培养基及分离培养方法
US11274279B2 (en) 2020-03-11 2022-03-15 Bit Bio Limited Method of generating hepatic cells
WO2022079272A1 (fr) 2020-10-15 2022-04-21 Katholieke Universiteit Leuven Hydrogels peptidiques à auto-assemblage sphéroïdaux comprenant des cellules

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ZHANG S. AND ALTMAN M. ET AL: 'Peptide self-assembly in functional polymer science and engieering.' REACTIVE AND FUNCTIONAL POLYMERS vol. 41, no. 1-3, pages 91 - 93, XP004172662 *
ZHANG S. ET AL: 'Self-complementary oligonucleotide matrices support mammalian cell attachment' BIOMATERIALS vol. 16, no. 18, 1995, pages 1385 - 1393, XP004032835 *
ZHANG S. ET AL: 'Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane' PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES. USA vol. 90, pages 3334 - 3337, XP008050522 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332336B2 (en) 2003-08-19 2008-02-19 Effector Cell Institute, Inc. Methods for inducing differentiation of pluripotent cells
WO2006038737A1 (fr) 2004-10-07 2006-04-13 Toyota Jidosha Kabushiki Kaisha Dispositif et procédé pour commander un moteur à combustion interne
EP1833504A2 (fr) * 2005-01-04 2007-09-19 The Brigham And Women's Hospital, Inc. Liberation prolongee de pdgf au moyen de nanofibres de peptides autoassembles
EP1833504A4 (fr) * 2005-01-04 2009-08-12 Brigham & Womens Hospital Liberation prolongee de pdgf au moyen de nanofibres de peptides autoassembles
WO2007000979A1 (fr) * 2005-06-27 2007-01-04 Menicon Co., Ltd. Peptide auto-assemble et gel fabrique a partir de ce peptide
JP4766528B2 (ja) * 2005-06-27 2011-09-07 株式会社メニコン 自己組織化ペプチドおよびそれより得られるゲル
US8299032B2 (en) 2005-06-27 2012-10-30 Menicon Co., Ltd. Self-assembling peptide and gel produced from the same
JPWO2007000979A1 (ja) * 2005-06-27 2009-01-22 株式会社メニコン 自己組織化ペプチドおよびそれより得られるゲル
US8697438B2 (en) 2005-09-30 2014-04-15 National University Corporation Okayama University Cell cultivation method and cell culture
US8647867B2 (en) 2005-09-30 2014-02-11 National University Corportion Okayama University Cell cultivation method and cell culture
JP5263756B2 (ja) * 2005-09-30 2013-08-14 国立大学法人 岡山大学 細胞の培養方法および細胞培養物
JP2007217376A (ja) * 2006-02-17 2007-08-30 Nagoya Institute Of Technology 自己組織化ペプチド組成物
JP2007217375A (ja) * 2006-02-17 2007-08-30 Nagoya Institute Of Technology 自己組織化ペプチド
US20110020452A1 (en) * 2006-08-22 2011-01-27 The Trustees Of Columbia University In The City Of New York Progenitor cell replication and differentiation in 3d
US8080418B2 (en) 2007-03-09 2011-12-20 Corning Incorporated Method of making a three dimensional cell culture matrix
WO2011072483A1 (fr) * 2009-12-14 2011-06-23 The University Of Hong Kong Compositions et méthodes permettant de contrôler la prolifération et la différenciation des cellules
US10612003B2 (en) 2010-10-27 2020-04-07 Upm-Kymmene Corporation Plant derived cell culture material
WO2012056110A2 (fr) 2010-10-27 2012-05-03 Upm-Kymmene Corporation Matière de culture cellulaire à base de cellulose microbienne
WO2012056111A2 (fr) 2010-10-27 2012-05-03 Upm-Kymmene Corporation Compositions d'administration de médicaments
EP2975115A1 (fr) 2010-10-27 2016-01-20 UPM-Kymmene Corporation Matériel de culture cellulaire d'origine végétale
WO2012056109A2 (fr) 2010-10-27 2012-05-03 Upm-Kymmene Corporation Matière de culture cellulaire d'origine végétale
US8546338B2 (en) 2010-12-08 2013-10-01 Johnson & Johnson Consumer Companies, Inc. Self-assembling hydrogels based on dicephalic peptide amphiphiles
WO2014049204A1 (fr) 2012-09-25 2014-04-03 Upm-Kymmene Corporation Culture de cellules tridimensionnelles
EP3699264A1 (fr) 2012-09-25 2020-08-26 UPM-Kymmene Corporation Culture de cellules tridimensionnelles
WO2016097490A1 (fr) 2014-12-18 2016-06-23 Upm-Kymmene Corporation Test de substance chimique
US10976308B2 (en) 2014-12-18 2021-04-13 Upm-Kymmene Corporation Plant-derived nanofibrillar cellulose hydrogel for cell culture and chemical testing
DE102015000363A1 (de) 2015-01-20 2016-07-21 Emc Microcollections Gmbh Neue modular funktionalisierbare Peptid-Hydrogele
WO2018234634A1 (fr) 2017-06-22 2018-12-27 Upm-Kymmene Corporation Échafaudage de cellulose nanofibrillaire de support pour l'expansion de cellules
EP3418377A1 (fr) 2017-06-22 2018-12-26 UPM-Kymmene Corporation Échafaudage de cellulose nanofibrillaire de support conçu pour développer des cellules
CN109810943A (zh) * 2019-03-21 2019-05-28 河南科技大学 一种猪肌源性间充质干细胞分离培养基及分离培养方法
US11274279B2 (en) 2020-03-11 2022-03-15 Bit Bio Limited Method of generating hepatic cells
WO2022079272A1 (fr) 2020-10-15 2022-04-21 Katholieke Universiteit Leuven Hydrogels peptidiques à auto-assemblage sphéroïdaux comprenant des cellules

Also Published As

Publication number Publication date
AU2003274900A8 (en) 2004-02-02
WO2004007683A3 (fr) 2005-09-09
AU2003274900A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
WO2002062969A9 (fr) Reprogrammation cellulaire dans un hydrogel peptidique et ses applications
WO2004007683A2 (fr) Reprogrammation cellulaire dans un hydrogel peptidique et utilisations associees
Stocum Stem cells in regenerative biology and medicine
Semino et al. Functional differentiation of hepatocyte-like spheroid structures from putative liver progenitor cells in three-dimensional peptide scaffolds
Tang et al. Embryonic stem cell-derived neural precursor cells improve memory dysfunction in Aβ (1–40) injured rats
US20070065942A1 (en) Human Renal Stem Cells
TW202022111A (zh) 來自肝外樹狀膽管的多潛能幹細胞及其分離方法
Santana et al. Insulin‐producing cells derived from stem cells: recent progress and future directions
EP2064319A2 (fr) Methodes de production de cellules gliales et neuronales et leur utilisation pour le traitement de troubles medicaux du systeme nerveux central
JP2023055732A (ja) 生物工学による組織のための組成物及び方法
US20200362315A1 (en) Formation of Three-Dimensional Organ from Pluripotent Stem Cells
CA2497954A1 (fr) Petites cellules pancreatiques et utilisations de ces dernieres
Mitaka Reconstruction of hepatic organoid by hepatic stem cells
Strick-Marchand et al. Embryonic liver cells and permanent lines as models for hepatocyte and bile duct cell differentiation
Strain Ex VivoLiver Cell Morphogenesis: One Step Nearer to the Bioartificial Liver?
EP2139989B1 (fr) Population isolee de cellules et procedes de generation et d'utilisation de celle-ci
Snyder et al. Transplantation and differentiation of neural “stem-like” cells: possible insights into development and therapeutic potential
AU2002248406A1 (en) Peptide scaffold encapsulation of tissue cells and uses thereof
US20230392123A1 (en) Spheroidal self-assembled peptide hydrogels comprising cells
WO2006128681A1 (fr) Souches endodermiques primitives, leurs procede de preparation et leur utilisation, en particulier pour l'obtention de cellules epitheliales hepatiques primitives
WO2004010933A2 (fr) Compositions cellulaires produisant de l'insuline et procedes associes
Brazelton et al. Plasticity of circulating adult stem cells
EP3935153A1 (fr) Induction géométrique de pluripotence
Deng Neurogenesis of adult stem cells from the liver and bone marrow
Li Differentiation of embryonic stem cells into neural lineages in an alginate encapsulation microenvironment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP